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CHAPTER 1

INTRODUCTION

Two pressing issues of public health concern are plaguing many parts of the
world today and are pervasive throughout nearly all age groups, genders, and
races. The first, obesity, has long been recognized as an ever-growing epidemic,
and extensive prevalence data exist reflecting its gravity. The second, vitamin D
deficiency, has only recently entered the public health consciousness, which is
why data on its prevalence are still incomplete, but nonetheless compelling. Both
represent conditions severe and widespread enough to warrant extensive study
accompanied by timely action. Moreover, these conditions may in fact be
interrelated.
__________________________________________________________________
Table 1.1 Body Mass Index

BMI =

weight (kg )
height (m 2 )

BMI

Weight Classification

< 18.5
18.5 – 24.9
25.0 – 29.9
≥ 30

underweight
normal/healthy weight
overweight
obese

__________________________________________________________________
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Obesity is characterized by excess body weight in the form of fat, and is defined
by a Body Mass Index (BMI) of ≥ 30 kg/m2 (Table 1.1). Excess body fat carries
with it a considerable risk for developing chronic diseases such as type-2diabetes and heart disease (Solomon & Manson, 1997).

The past 20 years have seen a very large increase in obesity in the United
States. Just looking at recent years reveals the extent of this development. In
1995, less than 20% of the population in each of the 50 states was obese. Only
five years later, in 2000, 22, or almost half the states in the U.S. had reached or
passed the 20% mark. Another five years later, in 2005, that number had more
than doubled to 46 states. Some states fared even worse. In 17 states, the
prevalence of obesity had risen to ≥25%, and to ≥30% in three states (Louisiana,
Mississippi, West Virginia). In 2006, the only state with <20% of its population
obese was Colorado. An additional 30% or more of each state’s population is
overweight, leaving less than half of the total U.S. population at a normal weight
[Centers for Disease Control and Prevention (CDC), 2007].

In Massachusetts, the prevalence of obesity has increased greatly in just the past
six years. In the 18-24 age group, it more than doubled from 7.4% in 1998 to
16.5% in 2006. The 25-34 age group experienced an increase from 13.4% to
16.5% in the same time period. Both genders are affected, although the increase
has been more pronounced in females than in males. While the prevalence of
obesity has increased most dramatically in those who have not completed high
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school, all educational levels are affected, including college graduates. Those
with some post-high school education as well as college graduates experienced
a rise in obesity prevalence from 13.5% and 11.1% in 1998 to 21.6% and 15.5%
in 2006, respectively [CDC Behavioral Risk Factor Surveillance System
(BRFSS), 2006].

Obesity is caused by an energy imbalance that occurs when more energy is
consumed than expended. Ultimately, excessive food intake and/or lack of
physical activity lie at the root of almost every case of obesity. However, while
the basic cause seems simple, a host of factors influences the two main
determinants. These include availability of energy-dilute foods such as fruits and
vegetables, opportunity for planned and incidental physical activity, emotional
factors governing eating behavior, as well as physical factors determining
appetite and energy expenditure.

As a species, humans have been able to maintain a constant body weight over
long periods of time without consciously matching energy intake to energy
output. Evolution has endowed us with an intricate hormonal system that, under
normal circumstances, is able to ensure a state of relative energy balance. One
of the major players in this system is leptin (Schwartz et al., 2000).

Leptin, the product of the ob gene, belongs to the group of adipokines (fat cell
secretory products) that are involved in maintaining energy balance. The

3

hormone initiates a pathway that induces energy expending processes while
suppressing appetite. In the control of food intake, leptin may elicit both shortand long-term responses. It may aid in controlling body weight by informing the
brain about the size of the body’s fat stores (Cohen, 2006). Simultaneously, it
may elicit a meal-specific satiety response to control short-term food intake (Pico
et al. 2003). In addition to influencing food intake, leptin stimulates energy
expenditure by inducing thermogenesis (Siegrist-Kaiser et al., 1997). Leptin acts
as a gene transcription factor (Zhang & Scarpace, 2006). It may therefore
regulate the expression of a number of proteins, both related and unrelated to
energy balance. Furthermore, the expression of leptin itself may be influenced by
other hormones. Limited evidence suggests that the active form of vitamin D may
be one such hormone (Menendez et al., 2001).

Vitamin D is a fat-soluble vitamin, the active form of which regulates the
expression of numerous genes, including those involved in serum calcium
homeostasis (Lips, 2006). In addition, the active form of vitamin D has been
identified as a modulator of cell differentiation and proliferation (Miyaura et al.,
1985; Tanaka et al., 1982). The most important source of vitamin D is
endogenous cutaneous synthesis as a result of sunlight exposure. Some plant
and animal products contain small amounts of the vitamin. However, natural food
sources are few, and cutaneous synthesis is affected by so many variables that it
by no means produces consistently sufficient quantities of vitamin D in many
populations (Holick, 2004a). Research over the past several decades has begun
to reveal the high prevalence of vitamin D deficiency that appears to span across
4

nations and populations (Calvo & Whiting, 2003; Chapuy et al., 1997;
Harinarayan et al., 2007; Oliveri et al., 2004; Zadshir et al., 2005). In addition,
new research into vitamin D’s calcemic and non-calcemic functions has spurred
debate surrounding a possible revision of the current Adequate Intake (AI) for
vitamin D, with many experts demanding it be increased (Dawson-Hughes et al.,
2005; Heaney, 2003; Holick, 2004a; Hollis & Wagner, 2004; Whiting & Calvo,
2005).

Poor vitamin D status often accompanies obesity (Arunabh et al., 2003;
Buffington et al., 1993). Conversely, numerous studies have confirmed that
serum leptin concentrations increase proportionally to body fat mass (Havel et
al., 1996; Considine et al., 1996; Rosenbaum et al., 1996). To date, only three
studies have evaluated the relationship between vitamin D and leptin, and only
one study has reported an inverse association between serum concentrations of
leptin and 25(OH)D3, the circulating form of vitamin D (Gomez et al., 2004). The
present study aims to evaluate this relationship in young women living in Western
Massachusetts as well as determine whether BMI and body fat mass modify this
relationship.

5

CHAPTER 2

VITAMIN D

The term vitamin D encompasses a number of metabolites as they occur in
animals and plants. Ergocalciferol, or vitamin D2, is the form of the vitamin found
in plants. Cholecalciferol, or vitamin D3, is the principal form of the vitamin and is
synthesized cutaneously by most animals, including humans, from 7-dehydrocholesterol. Both ergocalciferol and cholecalciferol can undergo two subsequent
hydroxylations in the body to yield, respectively, the circulating forms 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 (25(OH)D3), and the active forms, 1,25dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3 or calcitriol;
Fig. 2.1). Although in the United States ergocalciferol is sometimes used in
supplements and to fortify foods, it is utilized by the body only 20-40% as
efficiently as cholecalciferol (Holick, 2005).

Calcitriol has long been recognized as an indispensable regulator of serum
calcium homeostasis (Lips, 2006). Because of its ability to promote intestinal
calcium absorption, calcitriol furthermore contributes significantly to the
mineralization and maintenance of bone (Lips, 2006). Besides this primary
function, calcitriol has been recognized in recent years for its ability to induce cell
differentiation and inhibit proliferation in a number of tissues (Trump et al., 2004).
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In line with these findings, a number of epidemiologic studies point toward a
possible anti-tumorigenic role of vitamin D, possibly in the form of calcitriol
(Garland et al., 1989; Garland et al., 1990; Gorham et al., 2005; Grant, 2003). In
addition, a growing body of research is beginning to reveal a preventive role for
vitamin D in a host of other diseases, such as multiple sclerosis, cardiovascular
disease, and both forms of diabetes mellitus (Mathieu et al., 2005; Ponsonby et
al., 2002; van der Mei et al., 2003).
_________________________________________________________________
Ergocalciferol

Cholecalciferol

25(OH)D3

Calcitriol

Figure 2.1. Chemical forms of vitamin D
__________________________________________________________________

While present in a limited number of foods, the main source of vitamin D is
endogenous

synthesis

triggered

by

ultraviolet

radiation.

Subsequent

hydroxylations result in synthesis of the active form, calcitriol, which then acts via
two different mechanisms to influence biological pathways (Dusso et al., 2005;
Lips, 2006). Because endogenously synthesized vitamin D is difficult to quantify,
no Recommended Dietary Allowance (RDA) has been established, and current
recommendations are based on the estimated AI. Based on new evidence
concerning calcitriol’s role in calcium homeostasis as well as its possible
additional functions, a group of researchers is currently arguing for a revision of
the AI to reflect a growing body of evidence suggesting that physiologic needs
7

are higher than previously recognized (Dawson-Hughes et al., 2005; Heaney,
2003; Holick, 2004a; Hollis, 2005; Whiting & Calvo, 2005).

2.1

CUTANEOUS SYNTHESIS AND CONVERSION TO ACTIVE
FORM

2.1.1 Mechanism
Given sunlight exposure, the human body is capable of synthesizing vitamin D.
Triggered by exposure to UV-B radiation at wavelengths between 290-315 nm,
7-dehydrocholesterol (which is naturally present in the skin) is isomerized to
previtamin D3. Thermal transformation then causes the non-enzymatic
isomerization of previtamin D3 to vitamin D3. In this form, vitamin D3 can enter the
blood where it travels to the liver bound to vitamin D binding protein (DBP). In the
liver, the P450 enzyme CYP27A1 (25-hydroxylase) catalyzes the hydroxylation of
vitamin D3 to 25(OH)D3, the circulating form of the vitamin that possesses very
little biological activity. From the liver, 25(OH)D3 is distributed to all the tissues
containing vitamin D receptors (VDR), including the kidneys, bones, and
reproductive organs. When the need for vitamin D activity arises, 25(OH)D3
undergoes a second hydroxylation, catalyzed by CYP27B1 (1α-hydroxylase), to
1,25(OH)2D3 (calcitriol), a steroid hormone and the active form of the vitamin.
Although the second hydroxylation occurs primarily in the kidneys, many other
tissues have recently been shown to contain the 1α-hydroxylase necessary for
this step (Table 2.1). Following the second hydroxylation, renally hydroxylated
8

calcitriol acts as an endocrine hormone, while extrarenally hydroxylated calcitriol
is thought to act in an autocrine and paracrine fashion, specifically with respect to
cell differentiation (Lips, 2006).
_________________________________________________________________
Table 2.1. Selected Tissues and Cells Expressing the VDR and 1α-hydroxylase
VDR

1α-hydroxylase

kidneys
bones
brain
heart
skin
pancreatic β-islet cells
breast
prostate
colon
activated T and B lymphocytes

immune cells
colon
placenta
breast
prostate
pancreas

__________________________________________________________________

2.1.2 Influences on Cutaneous Synthesis and Vitamin D Status
Food sources of vitamin D include fatty fish (salmon, mackerel, sardines, etc.),
cod liver oil, as well as fortified versions of milk, orange juice, cereals, and some
other dairy products (Holick, 2004a). Table 2.2 lists the vitamin D content of
selected foods. A commonly consumed vitamin-D-containing food, fortified milk,
contains 98 IU per 1-cup serving (about half of the current AI for females up to
age 50). In contrast, 1 total-body minimal erythemal dose of sun exposure (MED,
the amount of sun exposure required to produce a slight pinkness of the skin)
results in the cutaneous synthesis of 10,000 – 20,000 IU (Hollis, 2005).
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________________________________________________________________
Table 2.2. Selected Food Sources of Vitamin D (IU)*
Cod liver oil, 1 tablespoon
Salmon, cooked, 3 ½ ounces
Mackerel, cooked, 3 ½ ounces
Sardines, canned in oil, drained, 1 ¾ ounces
Tuna fish, canned in oil, 3 ounces
Milk, nonfat, reduced fat, and whole,
vitamin D fortified, 1 cup
Ready-to-eat cereals fortified with 10% of the
Daily Value for vitamin D, ¾ cup to 1 cup
Orange juice, vitamin D fortified, 1 cup

1,360
360
345
250
200
98
40
100

Adapted from http://ods.od.nih.gov/factsheets/vitamind.asp#h2
*40 IUs = 1 µg vitamin D3

________________________________________________________________

Theoretically, the human body is capable of meeting its vitamin D needs through
sun exposure. However, cutaneous synthesis depends on so many variables that
vitamin D status is often inadequate, and vitamin D deficiency is a common
problem throughout the world. Vitamin D deficiency manifests as rickets in
children and as osteomalacia in adults. Both conditions are characterized by a
decrease in bone mineralization caused by impaired calcium absorption as a
result of insufficient mediation by calcitriol (Holick, 2004a).

Only a narrow range of wavelengths (290-315 nm UV-B) stimulates
photosynthesis of vitamin D3. Consequently, at certain latitudes, no vitamin D3 is
made during the winter months when sunlight meets the atmosphere at an
oblique angle causing most of the UV-B radiation to be absorbed by the ozone
layer. Any geographical area above a latitude of 37o in the Northern hemisphere
(such as Massachusetts) or below 37o in the Southern hemisphere supports
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virtually no vitamin D3 synthesis during the winter months (November through
February in the Northern hemisphere; Holick, 2004a).

Other risk factors for vitamin D deficiency include obesity, age, and skin color.
The ability to synthesize vitamin D3 decreases with age as 7-dehydrocholesterol
levels in the skin decline (MacLaughlin & Holick, 1985). The use of sunscreen
with a skin protective factor (SPF) of 8 or more inhibits synthesis by absorbing
UV-B radiation, as does the pigment melanin, meaning that cutaneous vitamin D3
synthesis is lower in individuals with dark skin (Holick, 2004a). In fact, very darkskinned persons need 120 minutes of peak summer UV-B exposure to
synthesize as much vitamin D3 (1 MED) as a light-skinned person can make in
10-12 minutes with comparable UV-B exposure (Hollis, 2005). Although
25(OH)D3 has a half-life of only two weeks, its fat-soluble precursor,
cholecalciferol, can be sequestered in body fat for use when cutaneous synthesis
is insufficient (such as in the winter; Holick, 2004b). However, in obese persons,
the excess fat is thought to provide such deep storage depots that cholecalciferol
sequestered there is difficult to mobilize, resulting in lower serum 25(OH)D3
concentrations (Wortsman et al., 2000).

Prolonged UV-B exposure does not result in excessive vitamin D3 synthesis,
because the pre-vitamin form is catabolized to lumisterol and tachysterol.
Furthermore, vitamin D3 is degraded to supersterol I, supersterol II, and 5,6trans-vitamin D3 in response to excessive UV-B exposure (Holick, 2000).
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However, toxicity can occur from excessive supplement intake. There is currently
no consensus as to the serum levels that have to be reached to produce toxicity.
Rizzoli et al. (1994) reported on seven cases of hypercalcemia that were
associated with plasma 25(OH)D3 levels ranging from 221 nmol/L (intake:
600,000 IU/wk or ~86,000 IU/d) to 1692 nmol/L (intake: 300,000 IU/d).
Supplemental vitamin D3 intake in these subjects ranged from 10,000 to 300,000
IU per day. The duration of supplement treatment prior to admission for
hypercalcemia was highly variable, but had been at least three weeks (Rizzoli et
al., 1994).

At high serum concentrations, 25(OH)D3 is capable of eliciting responses
mediated by the nuclear vitamin D receptor (VDRnuc). Considering that
hydroxylation to calcitriol is tightly controlled, toxicity is probably attributable to
high plasma levels of 25(OH)D3 rather than calcitriol. Vitamin D toxicity is
characterized by hypercalcemia, resulting in soft tissue calcification and kidney
stones. Other symptoms of vitamin D toxicity include hypercalciuria, anorexia,
nausea and vomiting, thirst, muscular weakness, joint pain, disorientation, and
eventual death if not treated (Norman, 2001).
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2.2

PATHWAYS OF ACTION

Calcitriol exerts its effects via two different pathways – genomic and nongenomic.
The genomic pathway begins with calcitriol binding to the VDRnuc. The ensuing
complex forms a heterodimer with the retinoic acid X receptor (RXR), and then
binds to a vitamin-D-responsive element on specific genes. Subsequently, a
number of transcriptional factors such as DRIP (vitamin D receptor-interacting
protein) attach to it, initiating or suppressing transcription and translation of the
vitamin-D-responsive gene (Lips, 2006).

The nongenomic pathway, or rapid response pathway, causes a much quicker
biological response than is achieved by gene transcription. It is thought to occur
as a result of calcitriol binding to receptors located on the outer plasma
membrane of cells (VDRmem). Two receptors – 1,25D3-MARRS and anexin II –
have been identified to date, although much remains to be learned about these
proteins (Dusso et al., 2005). Numerous studies suggest that an intricate
interplay, or “cross-talk,” takes place between the genomic and nongenomic
actions of calcitriol. Hence, the VDRnuc may be needed for nongenomic actions,
and nongenomic actions may influence calcitriol-induced gene expression.
However, these mechanisms remain to be elucidated (Dusso et al., 2005).
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2.3

PHYSIOLOGIC ROLES OF CALCITRIOL

2.3.1 Calcium Homeostasis and Bone Metabolism
Calcium homeostasis is one of the most tightly regulated systems in the human
body, relying on multilevel control mechanisms. When serum calcium levels drop
below 2.5 mmol/L, parathyroid hormone (PTH) is released by the parathyroid
gland, triggering a number of processes that help restore serum calcium levels to
normal. PTH results in the activation of renal 1α-hydroxylase, increased bone
resorption through activation of osteoclasts, and increased renal calcium
reabsorption (Holick, 2004a). Renal 1α-hydroxylase catalyzes the conversion of
25(OH)D3 to its active form calcitriol (Lips, 2006).

Calcitriol acts on several levels to normalize serum calcium concentrations. It
attaches to VDRs on intestinal enterocytes, which results in increased expression
of an epithelial calcium channel as well as increased expression of the gene
coding for calbindin and other proteins thought to facilitate calcium transport
across the enterocyte into the circulation (Holick, 2005). Calcitriol also facilitates
intestinal calcium absorption through the nongenomic pathway without mediation
by calbindin (Lips, 2006).

Calcitriol works in concert with PTH to cause an increase in bone resorption.
Calcitriol binds to VDRs in osteoblasts, triggering the expression of receptor
activator of nuclear factor-κB ligand (RANKL), which, in turn, binds to
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preosteoclasts, causing them to differentiate into mature osteoclasts. As
osteoclasts break down bone by releasing hydrochloric acid and collagenases,
calcium is freed from hydroxyapatite, the bone mineral complex, and released
into the circulation (Holick, 2004a and 2005).

The combined actions of PTH and calcitriol increase serum calcium levels by
enhancing dietary calcium absorption, reducing renal calcium excretion, and
mobilizing calcium stored in bone. In the absence of calcitriol, excess PTH is
produced, producing a condition known as secondary hyperparathyroidism. In
addition to its effects on calcium homeostasis, PTH also promotes urinary
phosphorus excretion, and secondary hyperparathyroidism results in excessive
urinary phosphorus loss and inadequate hydroxyapatite formation (Holick,
2004a). Over time, the metabolic responses to vitamin D deficiency result in
increased bone resorption and skeletal weakening.

2.3.2 Nontraditional Roles
Research over the last three decades has revealed the importance of vitamin D
in a number of physiologic responses apart from calcium homeostasis. The VDR
has been identified in a number of cells and organs, such as activated T and B
lymphocytes, β-islet cells, and cells in the prostate, breast, colon, and other
organs (Holick, 2004a). In addition, the 25-hydroxyvitamin D-1α-hydroxylase is
present in many extrarenal tissues and cells, such as immune cells and colon
cells, placenta, breast, prostate, and pancreas (Table 2.1; Martini & Wood,
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2006). Discovery of the widespread distribution of both the VDR and the 25hydroxyvitamin-D-1α-hydroxylase has triggered extensive research into their
functions.

Cell Proliferation and Differentiation in Relation to Cancer
Investigators found that extrarenally produced calcitriol acts as an autocrine and
paracrine hormone that inhibits proliferation and induces differentiation of normal
and some types of cancerous cells (Holick, 2004a). The first studies in this area
were done on leukemic cells. Tanaka et al. (1982) found that calcitriol inhibited
the proliferation of human leukemic cells by 50% and induced their differentiation
into mature granulocytes at concentrations of 0.12 nmol/L and above. Miyaura et
al. (1985) demonstrated calcitriol’s ability to suppress proliferation and promote
differentiation of human promyelocytic leukemia cells into macrophages. Since
then, this effect of calcitriol has been confirmed in many other cell types (Trump
et al., 2004).

Based on these findings, researchers hypothesized that calcitriol may have antitumorigenic properties. In support of this hypothesis, epidemiologic studies have
reported associations between geographical latitude and cancer risk. Breast
cancer mortality rates varied considerably between the southern and northern
United States, and the risk of fatal breast cancer decreased with increasing
strength of UV radiation (Garland et al., 1990; Bertone-Johnson et al., 2005).
Increasing latitude correlated with increasing prostate cancer mortality in a study
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of 3073 counties across the United States (Hanchette & Schwartz, 1992). Serum
25(OH)D3 concentrations of 20 – 26 ng/mL (~50 – 65 nmol/L) were associated
with a 52% lower colon cancer risk in a prospective study conducted in Maryland.
Risk decreased even further with increasing 25(OH)D3 concentrations up to
41 ng/mL (~100 nmol/L; Garland et al., 1989). Vitamin D intake of ≥1000 IU/day
or serum 25(OH)D3 levels of ≥33 ng/mL (~82 nmol/L) resulted in a 50% decrease
in risk for colorectal cancer (Gorham et al., 2005). In a European study, Grant
(2003) found that exposure to UV-B radiation and mortality rates were inversely
correlated for several cancers, including those of the bladder, breast,
endometrium, ovaries, prostate, and kidneys.

Multiple Sclerosis, Diabetes, and Heart Disease
Cancers are not the only diseases that may be influenced by vitamin D status.
Positive associations have been reported between latitude and the risk of
developing multiple sclerosis (Ponsonby et al., 2002). Risk of multiple sclerosis
was furthermore inversely correlated with amount of sun exposure during
childhood and adolescence in one study (van der Mei et al., 2003). Cutaneous
vitamin D3 synthesis may be the mediating factor in these relationships
(Ponsonby et al., 2002).

The presence of 1α-hydroxylase in the pancreas and the expression of the VDR
in pancreatic β-cells suggest that calcitriol may be involved in the insulin
response. In fact, vitamin D deficiency has been associated with the
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development of both type 1 and type 2 diabetes mellitus in humans (Mathieu et
al., 2005) and decreased insulin secretion in rats (Ayesha et al., 2001).
Furthermore, higher vitamin D intake in early childhood may be associated with
decreased risk of developing type 1 diabetes mellitus (Holick, 2004a).

Both multiple sclerosis and type 1 diabetes mellitus are autoimmune diseases.
The VDR is present on several immune cells, indicating that the binding of
calcitriol may elicit certain responses in these cells (Holick, 2005). In fact,
calcitriol is thought to exert some control over the immune system by acting as
an immunosuppressive agent (specifically by suppressing inflammatory T cells)
that is selective for autoimmune effects, but does not interfere with combating
opportunistic infections (Deluca & Cantorna, 2001). Calcitriol’s protective effects
against type 2 diabetes mellitus may be mediated by its proposed ability to
enhance pancreatic β-cell function and promote the biosynthesis of insulin
(Bourlon et al., 1999).

In 1997, Rostand reported that increasing latitude is correlated with the
prevalence of hypertension. To determine if vitamin D may be the mediating
factor in this relationship, Krause et al. (1998) evaluated this relationship and
showed that treatment with UV-B radiation increased circulating 25(OH)D3 and
decreased systolic and diastolic blood pressure. The mechanism of vitamin D’s
possible cardioprotective effect is not yet clear, but may be due to calcitriol’s
effect on blood pressure. Calcitriol downregulates renin (Li et al., 2002), an
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enzyme that increases blood pressure, and relaxes smooth muscle cells,
including those in the vasculature (O'Connell et al., 1994).

Inhibition of Adipogenesis
Cell culture studies over the past decade indicate a role for calcitriol in
adipogenesis. Many studies indicate an inhibitory effect (Kawada et al., 1996;
Kelly & Gimble, 1998; Sato & Hiragun, 1988), although some suggest that
calcitriol may act in a stimulatory fashion (Atmani et al., 2003; Bellows et al.,
1994). The molecular changes produced by calcitriol in the differentiating preadipocyte have not been extensively studied. The following paragraphs outline
the events of the adipogenic program as well as the intermediary steps that have
thus far been suggested to be responsible for calcitriol’s inhibitory effect.

Adipogenesis consists of a cascade of events that transforms pre-adipocytes to
mature adipocytes in a matter of several days. Differentiation factors initiate
mitotic clonal expansion (cell division) of the pre-adipocyte and induce
compounds such as CCAAT-enhancer-binding proteins beta and delta (C/EBPβ
and C/EBPδ). This is followed by the upregulation of the transcriptional
regulators C/EBPα and peroxisome proliferators-activated receptor gamma
(PPARγ). Subsequently, the cells continue to differentiate until they have
reached a terminal, mature state (Kong & Li, 2006).
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Calcitriol has been shown to influence the early stages of adipogenesis. When
added to a 3T3-L1 pre-adipocyte cell line at 0h, calcitriol inhibited adipogenesis
in a dose-dependent manner post clonal expansion by blocking the expression of
certain differentiation markers, including C/EBPα and PPARγ (Kong & Li, 2006).
In another study, calcitriol down-regulated the expression of C/EBPβ, which is
necessary for the induction of C/EBPα and PPARγ, and up-regulated expression
of ETO, an inhibitor of C/EBPβ action (Blumberg et al., 2006).

The unliganded VDR itself was capable of inhibiting adipogenesis when
overexpressed. With and without the presence of calcitriol, VDR inhibited PPARγ
transacting activity by competitively inhibiting heterodimer formation of PPARγ
with RXR (Kong & Li, 2006).

Because calcitriol affects compounds that appear early on in the adipogenic
program, addition after 48h did not have an effect. In the absence of calcitriol, the
VDR, which mediates the action of calcitriol, appears to decline in number after
4 – 8 hours. The window for calcitriol’s inhibitory effect is small, and arrested
differentiation of the pre-adipocyte appears to be completely reversible upon
removal of calcitriol. (Kong & Li, 2006).

Calcitriol may therefore be able to block some differentiation factors early on in
the adipogenic program, hence effectively halting adipogenesis and perhaps the
development of adiposity. Since adipocytes are not simply triglyceride-storing
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cells, but also secrete a number of hormones, such as leptin, calcitriol-mediated
inhibition would indirectly reduce the production of these hormones.

2.4

INTAKE RECOMMENDATIONS

Vitamin D status is assessed using serum levels of the circulating form 25(OH)D3
as an indicator. The traditional cut-off for deficiency is 27.5 nmol/L in children and
37.5 nmol/L in adults (Holick, 2004a). However, recent studies have called these
cut-off values into question. Vitamin D deficiency is currently defined as the
occurrence of the short-latency diseases rickets (in children) and osteomalacia
(in adults). Therefore, the 25(OH)D3 blood level below which these diseases
develop has been used to indicate deficiency. However, this definition leaves out
a number of long-latency diseases (e.g., osteoporosis and some cancers), whose
course is advanced when 25(OH)D3 levels fall below a much higher threshold
(Heaney, 2003). For example, an analysis of data from several thousand
participants from the third National Health and Nutrition Examination Survey
(NHANES III) revealed that bone mineral density (BMD) is positively correlated
with circulating 25(OH)D3 over a wide range of concentrations, including
concentrations greater than 37.5 nmol/L (Bischoff-Ferrari et al., 2004). The
currently accepted “optimal” value of 37.5 nmol/L is therefore by no means
associated with optimal BMD (Hollis, 2005).
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In search of an alternative standard, investigators now agree that maximal PTH
suppression and greatest calcium absorption should be used as indicators for
determining optimal circulating 25(OH)D3 values (Dawson-Hughes et al., 2005).
Estimates of 25(OH)D3 levels that produce these effects range from 40 to 110
nmol/L (Barger-Lux et al., 1998). Holick (2005) suggests a minimum 25(OH)D3
concentration of 50 nmol/L and an optimal concentration of 78-100 nmol/L.
Retention of the traditional deficiency cut-off value along with the development of
a new optimal concentration created a grey zone that was named “insufficient” or
“sub-optimal” vitamin D status. Eventually, this term should be abolished in favor
of a clear distinction between deficiency and sufficiency (Heaney, 2003).

Despite new recommendations, the establishment of an RDA remains a
challenging task since it is difficult to experimentally determine physiologic needs
given that the vitamin can be produced cutaneously. The current AI is 200 IU
(5µg) for children and adults under the age of 51, 400 IU for those aged 50 – 70
years, and 600 IU for those 71 years and older. But current intake
recommendations, like deficiency cut-off values, are set to prevent the shortlatency diseases rickets and osteomalacia, not long-latency diseases such as
osteoporosis, cancers, and autoimmune diseases (Whiting & Calvo, 2005). In
addition, meeting the current AI does not necessarily ensure blood levels of the
hitherto considered “adequate” value of 37.5 nmol/L (Nesby-O'Dell et al., 2002).
Hence, a revision of the recommended intake is clearly needed.

22

To maintain a minimum serum 25(OH)D3 level of 50 nmol/L, a daily vitamin D
intake of 600 IU is needed; a daily intake of 800 – 1000 IU results in an optimal
serum level of 75 nmol/L (Holick, 2004b). A weekly dose of 28,000 IU (about
twice the average amount of vitamin D produced in response to 1 total-body
MED) resulted in mean serum 25(OH)D3 levels of 112±41 nmol/L in those with
baseline serum levels of less than 60 nmol/L1 (Vieth et al., 2004). Hence, Holick
(2004a) proposes an AI of 800 – 1000 IU for those getting no sunlight exposure.
Although a multiple of the current AI, this recommendation still lies far below the
Upper Limit (UL) of 2000 IU/d as defined by the Institute of Medicine (Holick,
2004a).

1

It should be noted that the response to these intakes varies according to vitamin D status.

Persons with low baseline serum 25(OH)D3 levels experience a more pronounced increase (~1.0
nmol/L per 40 IU) in 25(OH)D3 than those with higher baseline levels of 70 nmol/L (~0.7 nmol/L
per 40 IU; Heaney et al., 2003).
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2.5

PREVALENCE OF DEFICIENCY

Studies conducted in recent years have begun to reveal the high prevalence of
vitamin D deficiency throughout the world and in many different population
groups (Calvo & Whiting, 2003; Chapuy et al., 1997; Harinarayan et al., 2007;
Lehtonen-Veromaa et al., 1999; Oliveri et al., 2004). Because of the UVabsorbing property of the pigment melanin and an age-related decline in levels of
7-dehydrocholesterol, dark-skinned and older persons would appear to be most
at risk. While these populations do experience much vitamin D deficiency, other
groups, such as young adult women, are substantially affected as well. Overall,
the groups most afflicted with vitamin D deficiency are women, non-white
persons, and the elderly (Calvo & Whiting, 2003; Oliveri et al., 2004; Zadshir et
al., 2005).

White (30%), Hispanic (42%), and African American (84%) elderly Bostonians
were vitamin D deficient at the end of August, a time of year when sunlight is
strong enough to support cutaneous vitamin D synthesis (Holick, 2004a). The
problem of vitamin D deficiency in the elderly is not limited to the United States.
Depending on latitude, 52% to 87% of healthy Argentinian elderly (65 years and
older) had 25(OH)D3 levels below 20 ng/mL (~ 50 nmol/L; Oliveri et al., 2004).

An analysis based on data taken from NHANES III, conducted from 1988 to
1994, reports deficiency in 42.4% of African American and 4.2% of white women,
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based on a conservative cut-off value of 37.5 nmol/L (Nesby-O'Dell et al., 2002).
While the percentage for white women appears low, the prevalence of deficiency
would have likely been higher if a more appropriate cut-off value of 80 nmol/L
had been used to define deficiency.

In fact, another group of investigators analyzing the same NHANES III data, but
with a different cut-off value, found the prevalence of deficiency (25 – 70 nmol/L)
to be ~78% in Black, 45% in White, and ~50% in all women 18 years and older.
The prevalence in all women was significantly higher than the prevalence in all
men (p<0.01; Zadshir et al., 2005). In the same study, fewer more-educated
women (more than high school) than less-educated women (less than high
school) were deficient (44% vs 59%), although deficiency was quite common in
both groups (Zadshir et al., 2005).

A combination of factors might be responsible for the difference in prevalence of
vitamin D deficiency between women and men. Women have more body fat, a
characteristic that has been associated with lower circulating levels of 25(OH)D3
(Wortsman et al., 2000). More women than men work in indoor professions,
limiting women’s exposure to sunlight (Fronczek & Johnson, 2003). Women
might be more health-conscious and therefore more likely to regularly use
sunscreen, a practice that inhibits the cutaneous synthesis of vitamin D (Abroms
et al., 2003). A focus on health and appearance may cause more women to
engage in dieting behavior that may manifest as kilocalorie restriction or
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avoidance of certain foods (e.g. dairy products; Kruger et al., 2004).

Such

restrictions can lead to reduced intake of vitamin-D-containing foods.

Although advanced age increases the risk for vitamin D deficiency, youth does
not protect from it. Tangpricha et al. (2002) reported vitamin D insufficiency
[based on a cut-off value of 50 nmol/L (=20 ng/ml) at the end of winter] in 36% of
healthy men and women between the ages of 18 and 29 living in Boston.

Stratifying by gender furthermore reveals the high prevalence of deficiency in
young women. In the NHANES III study, roughly 44% of women between the
ages of 18 and 39 years were deficient (Zadshir et al., 2005). Summer/higher
latitude and winter/lower latitude deficiency (<62.5 nmol/L) occurred in 30% and
55%, respectively, of 20- to 39-year-old women living at latitudes between 25o
and 41oN (Looker et al., 2002). Veith et al. (2001) reported that 21.3% of white,
31.9% of non-white, and 25% of black 18 – 35 year old Canadian females living
at latitude 43oN were deficient (<40 nmol/L) in the winter.

While men, Caucasians, and younger persons are less likely to be vitamin D
deficient, the prevalence of deficiency in these groups is still substantial (Calvo &
Whiting, 2003; Zadshir et al., 2005). Roughly 40% of a sample of male NHANES
III participants were deficient (25 – 70 nmol/L), 34% of whom were white and
37% of whom were between the ages of 18 and 39 years (Zadshir et al., 2005).
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The cut-off values used in these studies are mostly set above the traditional 37.5
nmol/L, but below 80 nmol/L, the level that has begun to emerge as an optimum
for preventing all vitamin-D-modified disease. Therefore, the percentages of
deficiency in these studies are conservative estimates which will increase once
the 80 nmol/L threshold is adopted by the public health community.

Deficiency occurs as a result of inadequate cutaneous synthesis and low dietary
intake. In an age of widespread sunscreen use or avoidance of sun exposure,
dietary and supplement sources ought to be emphasized to ensure adequate
vitamin D status. However, based on an analysis of Continuing Survey of Food
Intakes by Individuals (CSFII) and NHANES III data (Moore et al., 2004), dietary
vitamin D intake in the U.S. is low (even by the current AI) in those 51 years and
older (range of mean intakes: 160 – 236 IU) as well as in teenage and adult
females (range of mean intakes: 140 – 180 IU; Moore et al., 2004). Less than
30% of female adults (less than 20% in age group 19 – 30), less than 10% of 51
– 70 year olds, and less than 2% of those older than 70 years met requirements
through food alone. Supplement use increased the mean intake range to 210 to
393 IU, however less than a third of subjects in each age groups took a vitamin D
supplement (Moore et al., 2004).

Living at latitudes further from the equator increases risk for vitamin D deficiency
(Calvo & Whiting, 2003; Oliveri et al., 2004). In addition, intake of vitamin-Dcontaining foods is low, and less than a third of some high-risk populations meet
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the current AI, which itself is thought by many experts to be too low. Vitamin D
deficiency is more common in women than men, non-whites than whites, and
older than younger persons and is furthermore substantial in other groups,
including young adult women.

28

CHAPTER 3

LEPTIN

Leptin, the product of the ob gene, belongs to the group of adipokines that are
involved in maintaining energy balance. It was discovered along with its encoding
gene in 1994 by the research group of Jeffrey M Friedman (Zhang et al., 1994).
The name leptin was coined later on based on the Greek word for “thin” –
“leptos”. The 16-kDa hormone is produced mainly, but not exclusively, by white
adipocytes in proportion to fat mass and binds to receptors in the hypothalamus,
and possibly other tissues, to exert its appetite-suppressing and energyexpenditure-enhancing effects (Cohen, 2006; Considine et al., 1996; Maffei et al.,
1995).

Other tissues that express leptin include the placenta and stomach. A limited
body of studies suggests that gastric leptin may induce a short-term satietypromoting effect (Pico et al., 2002 and 2003). Ongoing research suggests that
leptin may also promote weight loss and maintenance by acting on adipocytes
directly, specifically by influencing lipogenic and lipolytic pathways (SiegristKaiser et al., 1997). However, while leptin is part of a hormonal system that helps
regulate energy balance, it neither prevents nor cures obesity. In fact, a
substantial increase in body fat mass is invariably accompanied by an increase in
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serum leptin levels and the physiologic effects of resistance to leptin (Considine
et al., 1996; Schwartz et al., 2000). In addition to its traditional role in weight
maintenance, leptin may also be involved in other body systems, including the
skeleton, the reproductive system, and the insulin response (Cohen, 2006;
Wauters et al., 2000).

3.1

LEPTIN AND OBESITY

The discovery of leptin was groundbreaking as it provided a possible biologic
cause for obesity, leading researchers to discard the long-held belief that obesity
is a purely behavioral condition. The first leptin studies were conducted with
knockout mice that lacked the ability to produce leptin due to a mutation in the ob
gene. This mutation led to uncontrolled food intake and obesity. Exogenous
leptin given to these mice resulted in decreased food intake and increased
energy expenditure leading to weight loss (Halaas et al., 1995; Pelleymounter et
al., 1995). This effect was subsequently observed in humans. Heymsfield et al.
(1999) showed that administration of exogenous leptin to lean and obese
subjects led to decreased energy intake and subsequent weight loss (95% of
which was fat loss) in a dose-dependent manner.
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3.1.1 Control of Food Intake
In the control of food intake, leptin may elicit two independent responses. Being
secreted proportionally to fat mass, it appears that leptin helps to inform the brain
about the size of fat stores in the body, thereby allowing for adjustments if fat
mass goes out of bounds in either direction (Cohen, 2006). This response is
mediated by the hypothalamus and promotes long-term weight regulation. While
circulating leptin concentrations are proportional to body fat stores, they are not
constant (Maffei et al., 1995), and fluctuations do occur in response to short-term
energy imbalance, such as short-term periods of overeating or starvation (Keim
et al., 1998; Weigle et al., 1997). The observations suggest that the more
sensitive responses to energy imbalance in the form of immediate satiety signals,
which are likely peripherally mediated, may help to promote the maintenance of a
desired level of body fat rather than substantial deviations from it followed by a
restorative period (Schwartz et al., 2000).

Hypothalamic regulation
The binding of leptin to receptors in the hypothalamus sets into motion a cascade
of neuronal signals that promote energy homeostasis. While leptin receptors are
present in different areas of the hypothalamus, the arcuate nucleus holds the
largest number per area, and it appears that this region is instrumental in the
leptin response (Schwartz et al., 2000).
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Leptin appears to influence the expression of several compounds involved in
appetite regulation. For instance, leptin receptors are present on neurons
expressing neuropeptide Y (NPY), agouti-related protein (AGRP), proopiomelanocortin (POMC), and cocaine- and amphetamine-regulated transcript
(CART), and it is thought that these molecules act as downstream mediators in
the leptin signaling response. The anabolic effector signaling molecules NPY and
AGRP appear to be downregulated by leptin, while their catabolic counterparts
POMC (the precursor of the melanocortin family) and CART appear to be
upregulated by leptin.

NPY is released in response to fasting and stimulates appetite. Increased
secretion of NPY in the paraventricular nucleus of rats was observed after a
period of fasting or prior to feeding in rats maintained on a feeding schedule
compared to rats fed ad libitum, indicating that NPY is released in response to
hunger. Food-deprived rats ate 5.3±4g compared to 1.0±8g (controls) during the
feeding period. NPY levels returned to control upon feeding (Kalra et al., 1991).
In another group of rats, NPY treatment led to increases in food intake, rate of
weight gain, and plasma leptin. Leptin administration repressed NPY production
in the arcuate nucleus, the paraventricular nucleus, and the dorsomedial
hypothalamus (Wang et al., 1997).

NPY mRNA levels are higher in the hypothalamus of the ob/ob mouse, which
does not express leptin (Wilding et al., 1993), indicating that leptin is necessary
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for NPY suppression. The double mutant NPY-/- ob/ob has a less obese
phenotype and less body fat than the ob/ob mouse, probably as a result of lower
food consumption and higher metabolic rate due to the missing NPY gene
(Erickson et al., 1996). These observations indicate that NPY mediates some,
but not all, of the outcomes associated with absence of leptin. In addition to
stimulating food intake and suppressing energy expenditure, the hypothalamic
NPY activates hepatic and adipose lipogenic enzymes (Schwartz et al., 2000).

POMC is the precursor molecule for melanocortins, molecules that are implicated
in the inhibition of ingestive behavior (Cohen, 2006; Schwartz et al., 1997). The
melanocortin system plays an important role in energy homeostasis. Disruption
of this system (e.g. by receptor mutation) has been found to lead to obesity and
diabetes symptoms in mice (Huszar et al., 1997). This effect might be explained
by the overexpression of NPY that results from mutation of melanocortin-4receptor (MC4R), the main receptor for α-MSH, one of the melanocortins (Cohen,
2006).

Neurons expressing the POMC gene also express the leptin receptor (Schwartz
et al., 1997), and binding of leptin appears to increase POMC expression. Db/db
mice, which lack the leptin receptor, and ob/ob mice express 46% and 70% less
POMC mRNA in the arcuate nucleus compared to wild-type mice. Intraperitoneal
leptin injection (150[Mu]g) increased POMC mRNA in ob/ob mice by 73%
compared to controls. No effect was seen in db/db mice, indicating that an
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interaction between leptin and its receptor (which is absent in db/db mice) was
responsible for the effect (Schwartz et al., 1997). Fasting, which downregulates
leptin, resulted in 53% less POMC mRNA in the rostral arcuate nucleus of wildtype mice (Schwartz et al., 1997). When wild-type rats were injected with
3.5[Mu]g of leptin during a period of fasting, POMC mRNA expression in the
rostral arcuate nucleus increased by 39% (Schwartz et al., 1997). These findings
support the idea that POMC expression is upregulated by leptin.

Similarly to POMC, CART is an anorexigenic neuropeptide, whose expression
also appears to be upregulated by leptin. Central administration of CART to
normal and NPY-treated rats resulted in decreased food intake (Kristensen et al.,
1998). Central administration of 1µg and 2µg CART to rats that had been fasting
for 24 hours decreased feeding by 59% and 68% compared to controls
(Kristensen et al., 1998). Rats injected with anti-CART (CART antiserum)
showed increased night-time feeding compared to controls (Kristensen et al.,
1998). Normal rats that had been fasted for 24 or 48 hours showed decreased
expression of CART mRNA in the arcuate nucleus and, though not significantly,
the dorsomedial hypothalamus (Kristensen et al., 1998). Obese Zucker rats
(fa/fa) and obese ob/ob mice, which express less CART mRNA than their wildtype counterparts were given daily intraperitoneal leptin injections. Ten days on
this regimen lowered food intake in the ob/ob mice (20±3g vs 43±3g in controls),
restored CART mRNA levels to normal in the arcuate nucleus and increased
levels in the lateral nucleus (Kristensen et al., 1998). These findings lend support
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to the theory that CART is an anorexigenic neuropeptide that is upregulated by
leptin.

Leptin seems to direct gene expression of these neuropeptides via different
pathways, the best characterized of which is the Janus tyrosine kinase 2/
cytosolic signal transducer and activator of transcription protein 3 (JAK2/STAT3)
pathway. Leptin binding stimulates the phosphorylation of the long form of the
leptin receptor (OB-Rb) by JAK2. This recruits STAT3 and prompts JAK2 to
activate STAT3 through phosphorylation. STAT3 subsequently splits into two
dimers that are translocated to the cell nucleus where they act as gene
transcription factors (Zhang & Scarpace, 2006).

Peripheral Regulation
In addition to central regulation, leptin may act peripherally to induce short-term
regulation of food intake. In a study with women, low levels of leptin were
associated with increased hunger, desire to eat, and prospective consumption
(Keim et al., 1998). The source of leptin required for this potential short-term
response is likely not the adipocyte. While circulating leptin levels decrease
almost immediately in response to fasting, they are not responsive to excess
food ingestion at a single eating occasion. Excess food ingestion has to occur
over a period of several days before leptin expression is upregulated in
adipocytes (Pico et al., 2003).
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The short-term effects of leptin may be attributable to gastric leptin, which may
work in conjunction with other satiety factors, such as cholecystokinin (CCK; Pico
et al., 2003). In fact, fasting appears to downregulate gastric leptin mRNA
expression in mice, while re-feeding appears to upregulate it (Pico et al., 2002).
Assuming that the absence of leptin induces a hunger sensation, blocking its
gastric synthesis in a fasted state may serve to prompt the animal to eat. Once
sufficient food has been ingested, gastric leptin may be needed to help initiate
the cessation of the meal.

The exact mechanism of gastric leptin action is not known. It is thought that it
acts via endocrine and paracrine routes. Gastric leptin is secreted by two types of
cells in the stomach, the chief cells, which also produce proteolytic enzymes, and
special endocrine cells, the P cells (Pico et al., 2003). Leptin could stimulate
nerve endings in the stomach and intestine, or it could act in the stomach lumen,
interacting with gastric epithelial cells (Pico et al., 2003). Gastric leptin is
probably not released into the circulation in sizable amounts and therefore does
not act substantially via direct brain receptor stimulation (Pico et al., 2003).

Ideally, the proposed effect of gastric leptin would protect against obesity by
preventing a prolonged state of positive energy balance from ever occurring.
However, while satiety factors influence meal size, research in mice and rats
suggests that they do not influence long-term energy balance when given
exogenously due to compensatory mechanisms, such as increased meal
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frequency (Pico et al., 2003). Gastric leptin may be subject to these same
compensatory responses.

3.1.2 Influence on Adipocytes and Lipolysis
In addition to providing satiety signals, leptin may influence fat mass directly by
inducing lipolysis and adipocyte apoptosis. Leptin-treated fat pads from SpragueDawley rats exhibited increased glycerol release – an indicator of lipolysis – in a
dose- and time-dependent manner, with leptin concentrations as little as
0.1 nmol/L showing an effect. A similar increase in glycerol release was evident
in fat pads of lean (Fa/fa) Zucker rats, while fat pads from their obese (fa/fa)
counterparts did not respond, implying that the lipolytic effect is mediated by
leptin through the long form of the leptin receptor (OB-Rb) which is not functional
in fa/fa Zucker rats.

Leptin’s lipolytic action appears to be mediated via the JAK2/STAT3 pathway.
Intravenous injection of 500 µg leptin into Fa/fa rats resulted in translocation of
STAT1 in brown adipose tissue. Leptin also increased STAT binding to nuclear
extracts in brown and white adipose tissue (BAT and WAT) cultures 1.8-fold and
2.7-fold, respectively. No STAT activation was observed in fa/fa derived cultures,
which do not express a functional leptin receptor. Since intracerebroventricular
(i.c.v.) injection had no effect, it appears that leptin induces lipolysis through
peripheral, rather than central, activation (Siegrist-Kaiser et al., 1997).
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Leptin may also promote weight loss by inducing adipocyte apoptosis. I.c.v.
infusion of 5µg and 2.5µg leptin into male and female Sprague-Dawley rats
resulted in apoptosis of white adipocytes (from retroperitoneal, epididymal, and
parametrial fat tissues) as evidenced by internucleosomal DNA degradation,
abnormal cell morphology, condensed chromatin in fat tissue sections, as well as
decreased weight and DNA content in fat pads. DNA degradation was not found
in other tissues, indicating that the apoptotic effect is restricted to adipocytes
(Qian et al., 1998).

3.1.3 Modification of Energy Expenditure
Leptin influences energy balance by stimulating energy expenditure. It induces
thermogenesis by causing the uncoupling of oxidative phosphorylation from the
electron transport chain (Fietta, 2005). Leptin given intravenously to male rats
resulted in a 1.6-fold increase in insulin-stimulated glucose utilization in brown
adipose tissue, an indicator of increased energy expenditure. This effect was not
observed when leptin was injected i.c.v., indicating that the effect is not mediated
via the brain, but is a direct action on the adipose tissue (Siegrist-Kaiser et al.,
1997).

3.1.4 Leptin Resistance
While early studies in leptin-deficient mice generated hope that obesity might
soon be treated pharmacologically, subsequent studies on humans showed less
promise. Leptin deficiency is extremely rare in humans. In fact, obese persons
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have much higher serum leptin levels (31.3 ± 24.1 ng/mL versus 7.5 ± 9.3 ng/mL;
Considine et al., 1996; Havel et al., 1996) and twice the ob mRNA than their lean
counterparts (Considine et al., 1996). This is not surprising considering that leptin
is made by adipose tissue and its serum concentrations increase proportionally
to fat mass (r = 0.85; Considine et al., 1996). It does, however, raise an important
question: If leptin helps regulate body weight, why do increased leptin
concentrations in obese individuals fail to bring about weight loss? These
seemingly contradictory findings led to the proposition that humans may become
resistant to leptin as their body weight increases, thereby preventing the weightreducing effect of leptin (Schwartz et al., 2000). A few different mechanisms
explaining this resistance have been proposed.

Impaired Transport across the Blood Brain Barrier
Leptin probably gains entry into the brain via leptin transporters. In leptin
resistance, transport of leptin across the blood-brain barrier may be impaired.
This theory is supported by the fact that the ratio of leptin in the brain to leptin in
the blood is lower in obese than in lean humans (Caro et al., 1996). As the brain
fails to receive leptin, adipocytes may be prompted to increase production,
leading to even higher levels in the blood (Schwartz et al., 2000).
This defect in transport may be exacerbated by a number of factors, including the
presence of certain triglycerides, as demonstrated by a series of experiments
conducted by Banks et al. (2004). During starvation (long-term food deprivation,
48 hours in this study), which leads to increased serum triglycerides due to
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lipolysis of stored fat, brain uptake of leptin was reduced by 44% as
demonstrated by a reduced brain/serum ratio of intravenously injected
radioactive leptin (I-Lep) in mice.

Injection of bovine whole milk, but not non-fat milk, into the mouse peritoneal
cavity resulted in impaired I-Lep transport across the blood-brain barrier, while
intralipid (a source of plant triglycerides) had no effect. Three of four different
intravenously injected triglycerides inhibited blood-brain barrier transport of I-Lep,
while one did not. Intravenously injected free fatty acids had no effect on I-Lep
transport. A high-fat diet increased serum triglycerides and decreased leptin
transport, while fasting (short-term food deprivation, 16 hours in this study),
which is characterized by a decrease in serum triglycerides, achieved the
opposite. Administration of Gemfibrozil, a triglyceride-reducing drug, decreased
serum triglycerides and increased leptin transport (Banks et al., 2004). Based on
these results in mice, it appears that some triglycerides, notably those from foods
of animal origin and those naturally released into the blood stream, may block
leptin transport across the blood-brain barrier.

To determine whether impaired leptin transport across the blood-brain barrier
precedes aging and obesity or is a result of these factors, Banks and Farrell
(2003) conducted a series of studies on CD-1 male mice. Aging brought about
considerable weight gain in the obese, but not the thin mice. Influx of I-Lep from
the blood into the brain dropped significantly with age in obese, but not thin mice,
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suggesting that the impairment of leptin transport across the blood-brain barrier
is acquired with weight gain. In addition, influx of I-Lep into the brain was
negatively correlated with body weight in 5-month old mice. Impaired leptin
transport seems to be reversible. In fat mice, weight loss through fasting or leptin
injection resulted in greater brain uptake of leptin compared to fat controls (Banks
& Farrell, 2003).

To locate the point at which leptin transport across the blood-brain barrier is
halted, Banks and Farrell (2003) employed capillary depletion, a technique used
to determine whether I-Lep is held in brain capillaries or crosses into the brain
parenchyma. Capillary depletion did not differ between thin and fat mice,
indicating that leptin was transported across the blood-brain barrier normally
once it had been taken up by the brain endothelial cells. Hence, the transport
defect must occur before leptin enters the brain endothelial cells.

Impairment of transport across the blood-brain barrier appears to be one
mechanism that can explain leptin resistance. Transport of leptin may be blocked
by certain triglycerides, notably those from foods of animal origin as well as those
naturally released into the blood stream. Mice acquired leptin resistance with
weight gain, and normal leptin function was restored with weight loss, indicating
that leptin resistance may be acquired with weight gain and reversible with
weight loss. The location of impaired transport remains unclear, but seems to
occur prior to uptake by the brain endothelial cells.
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Excess Central Leptin
According to the theory set forth above, leptin resistance results from leptin
deficiency in the brain. Contrary to this idea, another theory proposes that leptin
resistance results from excess central leptin. Zhang and Scarpace (2006)
artificially introduced the leptin gene into rats. This led to leptin overexpression,
decreased food intake, and increased oxygen consumption. However, this effect
disappeared toward the end of the observation period, indicating that excess
central leptin may lead to leptin resistance.

The attenuation of the effect happens more quickly in old-obese rats. Similarly,
5-month-old F344xBN rats with an artificially implanted leptin gene exhibited
reduced food intake and increased oxygen consumption, both of which
normalized half-way or two-thirds through the observation period. A 7-day
regimen of i.c.v. leptin in these rats did not reduce food intake as it did in controls
(Zhang & Scarpace, 2006). In addition, high-fat feeding resulted in markedly
higher energy consumption, greater weight gain, and greater visceral fat
accumulation in rats with the artificial leptin gene than in control rats, implying
that leptin resistance as brought about by excess central leptin mutes leptin’s
energy-compensatory response in the face of a high-energy diet (Zhang &
Scarpace, 2006).
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Defects in the Leptin Signaling Pathway
In addition to impaired transport across the blood-brain barrier and excess
central leptin, leptin resistance may manifest as a defective leptin signaling
pathway. To determine the point in the leptin signaling pathway at which a defect
occurs, Zhang and Scarpace (2006) tested events downstream of hypothalamic
leptin binding. Leptin increases the expression of POMC, the precursor for
melanocortins such as alpha-melanocyte stimulating hormone (α-MSH) that
binds to MC3R and MC4R to produce a decrease in food intake and an increase
in energy expenditure. Leptin resistance as brought about by age, excess leptin,
or diet coincided with impaired POMC expression and therefore decreased
melanocortin synthesis. Third ventricle infusion with MTII, a synthetic form of
α-MSH, allowed for typical leptin-related outcomes such as decreased food
intake and loss of adiposity and body mass by circumventing leptin-activated
melanocortin synthesis (Zhang & Scarpace, 2006). Similarly, artificial POMC
gene delivery to obese Zucker rats and rats with adult-onset obesity resulted in
leptin-related outcomes despite leptin resistance (Zhang & Scarpace, 2006).

These results indicate that leptin resistance occurs upstream of leptin-induced
neuropeptide expression. One of these upstream events is the JAK2/STAT3
pathway, as discussed earlier. Post-receptor-binding STAT3 phosphorylation is
part of this pathway. While leptin-activated phosphorylation of STAT3 to
P-STAT3 was similar in young-lean and old-obese F344xBN rats at low levels of
exogenous leptin given i.c.v., doses of 20ng of leptin and above resulted in a
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steeper increase in P-STAT3 concentrations in young than in old rats. The
maximum phosphorylation was 41% higher in young as compared to old rats.
P-STAT3 DNA binding, the final event in leptin-mediated gene expression, was
more than 8-fold greater in young-lean and less than 4-fold greater in old-obese
rats following 1µg leptin i.c.v. injection (Zhang & Scarpace, 2006). These data
suggest that obesity results in defects in the leptin signaling pathway at the
points of STAT3 phosphorylation and P-STAT3 DNA binding.

Diet Induced Leptin Receptor Deficiency
Experiments conducted by Zhang and Scarpace (2006) suggest that diet can
influence leptin receptor expression. High-fat feeding of young-lean F344xBN
rats for 100 days reduced leptin receptor expression, but increased basal leptin
signaling 3-fold, perhaps as a compensatory response. When these rats were
given i.c.v. injections of 2µg of leptin, STAT3 phosphorylation increased less than
2-fold as compared to chow-fed animals that experienced a greater than 6-fold
increase, perhaps reflecting the decreased number of leptin receptors or a dietinduced defect in the leptin signaling pathway. A 45-day long calorie restriction
followed by administration of 2µg of leptin increased the maximal STAT3
phosphorylation in both groups (Zhang & Scarpace, 2006), suggesting that highfat feeding had an inhibitory effect on STAT3 phosphorylation that disappeared
once the dietary factor had been removed.
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In another study, rats on a high-fat diet had a 22% reduced hypothalamic leptin
receptor expression compared to chow-fed rats. Caloric restriction increased
leptin receptor mRNA by 43% and 58% compared to chow-fed and non-calorierestricted high-fat fed rats, respectively (Zhang & Scarpace, 2006). High-fat
feeding in these studies appears to have blunted the leptin response by reducing
the number of leptin receptors or by interfering with STAT3 phosphorylation.

3.2

OTHER POSSIBLE LEPTIN TARGETS

3.2.1 Bone Growth and Maintenance
The idea that leptin may regulate bone mass was born from extensive and
conclusive research that positively correlates body weight and bone mineral
density (Albala et al., 1996; Kirchengast et al., 2002; Ribot et al., 1987; Seeman
et al., 1983). However, animal research in this area has produced somewhat
conflicting results that ascribe both inhibitory and stimulatory roles to leptin.
Leptin knockout mice have higher bone mass than wild-type mice, and i.c.v.
administration of leptin causes bone mass to diminish in these as well as normal
mice (Ducy et al., 2000). Conversely, leptin promoted bone growth upon
peripheral injection and in in vitro studies (Gordeladze et al., 2002; Steppan et
al., 2000). It seems, therefore, that depending on the site of leptin binding peripheral or central - the hormone elicits opposite responses with respect to
bone physiology.
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The peripheral effect seems to be mediated directly in bone tissue. A leptin
receptor has been identified in human osteoblasts, supporting a direct role of
leptin in these cells (Reseland et al., 2001). In fact, leptin stimulated
differentiation of marrow stromal cells into osteoblasts (Thomas et al., 1999),
inhibited differentiation of osteoclasts (Holloway et al., 2002), stimulated bone
mineralization and inhibited apoptosis of osteoblasts (Reseland et al., 2001;
Gordeladze et al., 2002).

The central effect appears to be mediated via the hypothalamus. Neurons in the
ventromedial nucleus of the hypothalamus have been associated with bone mass
regulation via two proposed pathways. Contrary to the evidence put forth by the
animal studies cited above, these proposed pathways elicit opposite outcomes.
The sympathetic nervous system (SNS) pathway starts with noradrenalin binding
to the osteoblastic receptor β2-AR, which then produces the receptor RANK.
When nuclear factor kappa beta (NFκB) binds to RANK, osteoclasts mature and
begin the resorption of bone. Leptin initiates this pathway, but also activates a
less well studied antagonistic pathway, the CART pathway, that leads to
inhibition of osteoclast differentiation, and therefore prevents resorption. Absence
of CART leads to osteoporosis in mice. NPY2R, one of NPY’s receptors, is
postulated to play a role in bone mass as well (Elefteriou et al., 2005; Cohen,
2006). Leptin’s capability to activate both the bone-building SNS and the boneresorbing CART pathway, indicates that leptin may act as a regulator of bone
mass.
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In an effort to determine the significance of leptin in human bone metabolism, an
epidemiologic look reveals an inconclusive picture. Some studies on adult
women have found no association between leptin and BMD (G. Martini et al.,
2001; Ruhl & Everhart, 2002) or markers of bone metabolism (Goulding & Taylor,
1998; Martini et al., 2001; Rauch et al., 1998), especially after adjusting for BMI.
Others confirm a positive correlation between plasma leptin and BMD in
premenopausal (Thomas et al., 2001) and postmenopausal (Thomas et al., 2001;
Yamauchi et al., 2001) women, and an inverse correlation in men (Ruhl &
Everhart, 2002; Sato et al., 2001). Pasco et al. (2001) found associations only for
specific skeletal sites in non-obese women (e.g. lateral spine).

3.2.2 The Insulin Response
In addition to being obese, mice with the ob/ob defect are insulin resistant, and
administration of leptin reverses their hyperglycemia, hyperinsulinemia, and
insulin resistance (Muzzin et al., 1996; Pelleymounter et al., 1995). Central and
peripheral leptin administration increased insulin sensitivity in mice and rats
(Sivitz et al., 1997; Kamohara et al., 1997). Increased leptin levels have been
observed in humans with type 1 and type 2 diabetes as well as those with
artificially induced hyperinsulinemia (Wauters et al., 2000). In addition, serum
leptin and insulin have been positively correlated (Widjaja et al., 1997). Leptin
expression was induced by insulin in vitro at 72h (Kolaczynski et al., 1996). On
the other hand, leptin may initiate SOCS3 action, which inhibits both leptin and
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insulin signaling (Myers, 2004; Cohen 2005). The evidence linking leptin and the
insulin response is inconclusive, suggesting both an insulin-supporting and an
insulin-inhibiting role for leptin.

3.2.3 Reproduction
The observation that ob/ob mice are sterile led to the idea that leptin may be
instrumental in puberty, menarche, and menstruation. In the few human subjects
that have an ob/ob or leptin receptor mutation, puberty is delayed (Wauters et al.,
2000). In girls, both menarche and menses require maintenance of a certain level
of fat mass. Recognizing that serum leptin rises proportionally to fat mass, it
seems plausible that leptin may be involved in the reproductive system. Several
studies provide evidence in support of this idea.

For instance, Chehab et al. (1996) reported that leptin treatment is capable of
reversing reproductive impairment in ob/ob male and female mice. In girls, a rise
in leptin preceded onset of puberty (Garcia-Mayor et al., 1997), indicating that
leptin may be involved in mediating the hormonal changes leading to
reproductive maturation. In rodents, centrally acting leptin is furthermore capable
of triggering the release of follicle stimulating hormone (FSH) and luteinizing
hormone (LH), both of which are essential to the reproductive cycle (Wauters et
al., 2000). Conversely, estrogens and FSH stimulate leptin secretion in vitro in
human female, but not male, tissue samples, while androgens inhibit leptin
secretion. In addition, leptin and a soluble form of its receptor are expressed in
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the placenta, and leptin levels fluctuate throughout the menstrual cycle and are
elevated during pregnancy (Wauters et al., 2000). These findings indicate that
leptin may support normal reproductive function, including onset of puberty,
menses, and pregnancy, perhaps through bi-directional interaction with sex
hormones.

49

CHAPTER 4

RELATIONSHIP BETWEEN LEPTIN AND VITAMIN D

The study of the interactions between leptin and vitamin D is a new area of
interest, and few studies have examined the potential relationship between the
two compounds. Results from these studies provide evidence that vitamin D and
leptin do regulate each other.

In an attempt to isolate factors that regulate leptin secretion, Menendez et al.
(2001) added 3,5,3’-tri-iodothyronine, calcitriol, and retinoic acid concentrations
of 10-9, 10-8, and 10-7 M, respectively, to human male and female omental
adipose tissue. In addition, a mixture of all-trans-retinoic acid and calcitriol
combined at a concentration of 10-7M was tested. At all concentrations tested,
calcitriol inhibited leptin secretion within 96 hours of exposure, especially at 72 h
and 96 h at 10-7 and at 96 h at 10-8M. Calcitriol and all-trans-retinoic acid together
inhibited leptin secretion in a synergistic manner at 72 h.

While Menendez’s results indicate that calcitriol is a regulator of leptin secretion,
a study by Matsunuma et al. (2004) suggests that leptin influences calcitriol
synthesis. Matsunuma et al. injected obese ob/ob mice with leptin to measure the
effect of exogenous leptin on a number of bone-related variables. Because of
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their genetic mutation, the mice exhibited several abnormalities. These included
elevated concentrations of calcitriol, renal 1α-hydroxylase, 24-hydroxylase
mRNA, serum Ca2+ and phosphorus, increased excretion of Ca2+ and
phosphorus, higher activity of serum alkaline phosphatase (a marker of bone
formation) and TRAP (a marker of bone resorption), and decreased BMD and
femoral length. Injection with recombinant murine leptin at 4 mg/kg every 12h for
2d corrected some of these abnormalities. Elevated calcitriol decreased to the
level observed in control mice (table 4.1). In accordance, renal 1α-hydroxylase
and 24-hydroxylase mRNA as well as serum Ca2+ and phosphorus decreased to
normal. Serum PTH concentrations increased. VDR expression did not change
with leptin deficiency or administration.
_________________________________________________________________
Table 4.1. Effect of leptin treatment on elevated calcitriol levels
Treatment condition

1,25(OH)2D3

ob/ob mice without leptin injection
ob/ob mice after leptin injection
control mice (not leptin deficient)

174 +/- 11.2 pg/ml
85 +/- 7.7 pg/ml
81 +/- 3.7 pg/ml

_________________________________________________________________

An interaction between calcitriol and leptin is evident from the results of the
Menendez (2001) and Matsunuma (2004) studies. While plasma levels of
calcitriol and 25(OH)D3 generally are poorly correlated, 25(OH)D3, which serves
as the biomarker for vitamin D status, is the precursor of calcitriol and therefore
necessary for its synthesis. In the only human study to examine the relationship
between 25(OH)D3 and leptin, Gomez et al. (2004) found a negative correlation
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between the two compounds in women without vitamin D deficiency. This
analysis was part of a study that also looked at the insulin-like growth factor I
(IGF-I) system as well as anthropometric and body composition variables as
predictors of 25(OH)D3.

Gomez et al. (2004) studied 253 subjects (126 men, mean age 41.6 years; 127
women, mean age 40.8 years) from the Spanish town of L’Hospitalet de
Llobregat. Participants were healthy and were not attempting weight loss by
means of diet or exercise during the study period. Subjects were excluded from
the study if they had a history of thyroid dysfunction or had a history of treatment
with thyroid hormone, calcium, vitamin D, steroids, or thiazides. Anthropometric
data included BMI, waist and hip circumference, waist-hip ratio, and body
composition, as measured by bioelectrical impedance. Radioimmunoassay kits
by Linco and DiaSorin were employed to measure serum leptin and 25(OH)D3,
respectively. Spearman’s correlation coefficient and multivariate linear regression
were used to determine relationships among variables.

Of the 253 subjects, 45 were vitamin D deficient (defined in this study as serum
25(OH)D3 < 38 nmol/L), and 24 were severely deficient (serum 25(OH)D3 < 25
nmol/L). Vitamin D status varied by season. Serum 25(OH)D3 concentrations
were 73.9 ± 16.4 nmol/L in the summer, 53.9 ± 18.1 nmol/L in the fall, 39.6 ± 16.7
nmol/L in the winter, and 46.7 ± 15.5 nmol/L in the spring. BMI, hip
circumference, and fat mass were significantly lower and IGF-I levels were
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significantly higher in non-deficient subjects than in those with vitamin D
deficiency. An inverse trend with decade of age was observed in 25(OH)D3 levels
in both genders. In men, leptin levels were relatively constant across age groups,
while in women serum leptin was twice as high in the oldest compared to the
youngest age group.

In women without vitamin D deficiency (serum 25(OH)D3 ≥ 38 nmol/L), a negative
correlation was observed between 25(OH)D3 and age, BMI, waist and hip
circumferences, fat free mass, fat mass, and leptin. In both men and women with
vitamin D deficiency, no correlations between serum vitamin D and any of the
variables were found. The authors suggest that leptin – among other factors –
may play a role in the regulation of 25(OH)D3 concentrations in women. Gomez
et al. concluded that an inverse correlation exists between serum leptin and
25(OH)D3 (Gomez et al., 2004). However, because of its cross-sectional design,
this study does not provide evidence for causality.

These three studies provide evidence that vitamin D and leptin interact with each
other. It appears that calcitriol and leptin may be capable of regulating each
other, perhaps depending on initial concentration and type of tissue. Leptin and
25(OH)D3 were correlated in women with adequate vitamin D status, but not in
men, suggesting a gender difference with respect to the interaction between the
compounds.
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CHAPTER 5

PURPOSE OF THE STUDY

Obesity continues to be on the rise worldwide. Any factor that contributes to the
obesity epidemic needs to be identified. Considering the call for increased
recommended intake levels of vitamin D, it is important to understand how such
revisions might influence other factors, such as leptin expression, not traditionally
associated with the vitamin. While research on leptin has been extensive, much
remains to be learned about the variables influencing its expression.

Tissue culture and animal studies by Menendez et al. (2001) and Matsunuma et
al. (2004) suggest interplay between leptin and calcitriol. In addition, leptin could
influence the expression of the hydroxylating enzymes responsible for converting
vitamin D into its different forms. Furthermore, the inhibitory influence of calcitriol
on adipogenesis could indirectly lower leptin expression. Calcitriol synthesis
depends on the presence of its precursor, 25(OH)D3. Gomez et al. (2004)
showed an inverse correlation between serum leptin and serum 25(OH)D3 in
women without vitamin D deficiency.

The objective of the current study is to examine the relationship between serum
concentrations of leptin and 25(OH)D3 in healthy 18- to 30-year-old women at the
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University of Massachusetts. More specifically, this study will determine whether
serum leptin is a significant predictor of serum 25(OH)D3.

In addition, our

analysis will determine whether this relationship is independent of BMI and body
composition. The results from this study will lead to a more complete
understanding of the factors that influence adiposity and will help to inform
discussions concerning revision of dietary vitamin D recommendations.

5.1

HYPOTHESES AND SPECIFIC AIMS

Hypotheses:
• Leptin is positively correlated with BMI and body fat mass.
• 25(OH)D3 is inversely correlated with BMI and body fat mass.
• Leptin and 25(OH)D3 are inversely correlated.
• The relationship between leptin and 25(OH)D3 depends on or is modified by
BMI and/or body fat mass.

Specific Aims:

1. Determine the relationship between serum concentrations of leptin and
25(OH)D3.
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2. Determine the relationship between the aforementioned biomarkers and
BMI.
a) Determine the relationship between serum leptin concentrations
and BMI.
b) Determine

the

relationship

between

serum

25(OH)D3

concentrations and BMI.

3. Determine the relationship between the aforementioned biomarkers and
body fat mass.
a) Determine the relationship between serum leptin concentrations
and body fat mass.
b) Determine

the

relationship

between

serum

25(OH)D3

concentrations and body fat mass.

4. Statistically determine whether body fat mass or BMI significantly
confound or modify the relationship between leptin and 25(OH)D3.
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CHAPTER 6

MATERIALS AND METHODS

6.1

SAMPLE

As part of the University of Massachusetts Vitamin D Study, female subjects
between the ages of 18 and 30 were recruited from the Western Massachusetts
population (mostly from the UMass Amherst campus) during the spring of 2006
and the 2006-2007 school year. Women were excluded from the main study if
they were pregnant and/or had any of the following conditions: high blood
pressure, kidney diseases, liver diseases, bone diseases (e.g. osteopenia,
osteomalacia), digestive disorders (e.g. celiac disease, Crohn’s disease,
ulcerative colitis), rheumatologic diseases (e.g. rheumatoid arthritis), multiple
sclerosis,

thyroid

diseases

(e.g.

Grave’s

disease,

hyperthyroidism,

hypothyroidism, benign thyroid nodules), cancer, type 1 or type 2 diabetes,
depression, hyperparathyroidism, elevated cholesterol or hyperlipidemia, and
polycystic ovaries or polycystic ovarian syndrome. Women who took the following
medications were also excluded from the study: corticosteroids, anabolic
steroids, anticonvulsants, Propranolol, Tagamet and Cimetidine. The current
study included the first 46 subjects for whom both biomarker and Dual Energy
X-ray Absorptiometry (DXA) measurements were available.
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6.2

DATA COLLECTION

6.2.1 Collection of Dietary and Demographic Data
Each woman was required to complete one study visit, which was scheduled
during the late luteal phase of her menstrual cycle, three to five days before the
expected start of the next menstrual period. At that visit, women completed the
Harvard food frequency questionnaire (FFQ) and a questionnaire designed
specifically for this study to elicit demographic as well as health-related data.

The Harvard FFQ has been validated and was found to correlate well with
multiple one-week diet records with respect to its ability to quantify nutrient
intake, especially after adjustment for total caloric intake (r = 0.36 to 0.75
depending on nutrient). Repeat administration was shown to result in reasonable
reproducibility (r = 0.49 to 0.71 depending on nutrient; Willett et al., 1985). With
respect to the assessment of intake of individual foods, the FFQ also produces
reproducible (r = 0.31 to 0.92 depending on food item, mean r = 0.59) and valid
(r = 0.17 to 0.95, mean r = 0.63) results as compared to two one-week diet
records (Feskanich et al., 1993).

The FFQ queries about common food sources of vitamin D (milk and fatty fish)
as well as foods that may or may not contain the vitamin, depending on the
manufacturer’s fortification practices (yogurt, cheese, breakfast cereals). An
open-ended question about the type and brand of the respondent’s breakfast
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cereal allows for the quantification of vitamin D intake from this frequently
consumed food category.

There are nine response options for foods ranging from never or less than once
per month to six or more times per day. The FFQ contains a section on vitamin
supplements, including multiple vitamin preparations. The response options for
multiple vitamins range from two or less to 10 or more per week. Participants are
furthermore asked to indicate brand and type of multivitamin used. Although a
vitamin D supplement is not listed in a category of its own, it is listed as a choice
under other regularly consumed supplements. The Harvard FFQ was adapted for
this study to inquire about the previous two months instead of one year and to
include additional foods (vitamin-D-fortified orange juice, soy products).

6.2.2 Measurement of BMI
Height was measured to the nearest 0.5 centimeter using a wall-mounted
stadiometer. Weight was measured two ways, using the Detecto beam balance
scale and using the DXA scanner. With either method, weight was measured to
the nearest 0.1 kilogram. Since all body composition data are based on DXA
measurements, DXA measurements of weight were also used to calculate BMI.
Waist circumference to the nearest 0.5 inch was measured using a measuring
tape. Measurements were performed fasting and without shoes. Subjects were
allowed to have water the morning of the visit.
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6.2.3 Measurement of Body Composition
Body composition was obtained either on the same day or at a second visit using
the General Electric Prodigy DXA scanner. In addition to the yearly preventive
maintenance check, a calibration scan is run daily on the machine. All DXA
scans was performed by trained study personnel. DXA’s main advantage in
estimating body composition is its ability to measure the three main body
components (bone, soft lean tissue, and fat) directly. Other methods measure
only one and use extrapolation to obtain results for the others. Compared to
similar methods, such as dual photon absorptiometry (DPA), DXA uses a more
stable source of radiation, thought to decrease precision error (Haarbo et al.,
1991). Studies by both Haarbo et al. (1991) and Mazess et al. (1990) report
reasonable precision errors for percent fat (SD 1.6% and 1.4%) and fat mass (SD
1.1 kg and 1.0 kg). Using ox inner thigh, porcine lard, and mixtures of the two,
Haarbo et al. (1991) detected an accuracy error of 4.9% when comparing DXA
measurements of percent fat with results from chemical fat extraction. The
authors regard this error as satisfactory for both research purposes and
diagnosis of the individual patient.

6.2.4 Specimen Collection and Biomarker Assay
Fasting venous blood was collected into serum separator vacutainers (SSTTM
Plus Blood Collection Tubes by Becton Dickinson) and kept on ice until serum
was separated. Blood samples were centrifuged at 3000 x g for 15 minutes, and
the serum was aliquoted into multiple cryotubes and stored at -80oC until
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biomarker assessment. Serum 25(OH)D3 concentrations were determined using
a radioimmunoassay (RIA) kit (DiaSorin, Minnesota, USA). This assay has been
validated by numerous investigators (Hollis, 2000). Serum leptin concentrations
were similarly assayed using a RIA kit (Linco, St. Charles, MO; Ma et al., 1996).
Gamma irradiation (in counts per minute) was quantified using a Beckman
“Gamma 4000” gamma counter (Beckman Coulter, California, USA). RIA
analysis involves extraction and preparation of the sample followed by
measurement of gamma counts per time unit for each sample, which are plotted
against a standard curve to determine biomarker concentrations. The
calculations are outlined in table 6.1. The study was approved by the Human
Subjects Committee of the University of Massachusetts, and each subject
provided written informed consent.

_________________________________________________________________
Table 6.1. RIA Calculations
1. Average duplicate counts.
2. Subtract non-specific-binding counts from each average count (except for Total Counts)
3. Calculate the percentage of tracer bound:
% tracer bound = (total binding counts/total counts) x 100
4. Calculate the percentage of total binding:
%B/Bo = (sample or standard/total binding) x 100
5. Plot %B/Bo for each standard on the y-axis and the known concentration on the x-axis
using log-log graph paper.
6. Construct a reference curve from these points.
7. Interpolate the reference curve to determine concentrations of the unknown samples.
Adapted from LINCO Research RIA Kit instruction brochure

_________________________________________________________________
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6.3

STATISTICAL ANALYSIS

Data were summarized using mean ± SD for continuous and percentages for
categorical variables. Leptin was logarithmically-transformed using the natural
logarithm (ln), because it was not normally distributed. Dietary variables were
dichotomized to show how many subjects did not meet the RDA. Serum
25(OH)D3 concentration was divided into three categories to determine
prevalence of deficient and suboptimal vitamin D status. Mean 25(OH)D3 was
stratified by month and season and compared using the Welch statistic.
Tamhane’s test was used for post hoc analyses. Welch and Tamhane were used
because the groups did not have equal variances.

Characteristics of study subjects were stratified by vitamin D status and
differences between strata were determined with ANOVA. The Welch statistic
was used for variables with unequal variances as determined by Levene’s test.
Contrast tests did not reveal any differences between the “deficient” and
“suboptimal” groups, so these groups were collapsed into one “insufficient”
group, and differences were again determined with regular ANOVA or Welch.
Chi-square statistics were computed for several sun exposure variables to
determine whether differences in the proportion of these variables between
vitamin D status strata were likely due to chance. Serum 25(OH)D3 was stratified
by several sun exposure variables and differences between strata were
determined using regular ANOVA or Welch.

62

To determine correlations, variables that were not normally distributed were lntransformed. Pearson’s rho was used for all dietary variables, except for total
vitamin D, vitamin D from food, and vitamin B6. Correlations for the latter three
were assessed using Spearman’s rho. For Pearson’s correlations, ln-transformed
values were used for all variables except energy, vitamin A, and 25(OH)D3, which
were normally distributed.

The associations between body composition measures, 25(OH)D3, and leptin
were assessed using correlation analysis (Pearson’s rho), followed by further
analyses using bivariable and multivariable linear regression. Covariates
included in the regression models were BMI, FM, %BF, age, smoking status, and
sunscreen use. The leptin-25(OH)D3 relationship was further evaluated for effect
modification by %BF and BMI. The data were stratified by %BF (cut-off 30%).
Beta coefficients were calculated for each stratum using the same multivariable
linear regression model as for the un-stratified analysis. Any differences in the
beta coefficients were evaluated for statistical significance by re-running the
regression model with a multiplicative interaction term. The multiplicative
interaction term was created by multiplying the continuous variable ln(leptin) with
the dichotomous stratification variable that identified women as having normal or
high body fat. The significance level was set at p=0.05 for all analyses. The
Statistical Package for Social Sciences (SPSS, Windows version 15.0, SPSS Inc.
Chicago IL, USA) was used for all analyses.
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Chapter 7

RESULTS

Characteristics of the study sample are shown in Table 7.1. Most participants
had waist circumferences of 88 cm or less (n=42) and BMIs between 18.5 kg/m2
and 25 kg/m2, with a mean of 21.9 kg/m2 (n=35). Four women (8.7%) had BMIs
below 18.5 kg/m2, and seven women (15.2%) had BMIs above 25 kg/m2.
However, the sample shows considerable variability with respect to body fat
percentage (%BF). Women were about equally divided into high (%BF>30, n=26)
and normal (%BF≤30, n=20) body fat groups with values ranging from 14.5 to
45.2%. Mean serum leptin was 10.1 ± 6.8 ng/mL. Mean serum 25(OH)D3 was
105.4 ± 38.0 nmol/L. About half of women (n=25) reported using sunscreen. One
participant indicated that she was currently a smoker, and seven participants said
they used to smoke (data not shown).

Mean intakes of energy, macronutrients and select micronutrients are shown in
Table 7.2. Almost all women (≥95%) consumed at least the RDA for phosphorus,
niacin, riboflavin, and vitamins A, B6, and B12. Vitamin D intake from food and
supplements ranged from 22 IU to 1446 IU. Mean vitamin D intake was 367 ±
242 IU, but almost one fourth (22%) of participants did not meet the current AI for
vitamin D (200 IU), and 96% of women consumed < 800 IU, the lower limit of the
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vitamin D requirement proposed by Holick (2004b; data not shown). Calcium
requirements were not met by 35% of the study sample.

Table 7.1. Characteristics of Women in the Study Sample1
Mean ± SD
Age
Weight (kg)
Weight (kg) based on DXA
Height (cm)
Body Mass Index, BMI (kg/m2)
Waist Circumference (cm)
Fat Mass (kg)
Body Fat Percentage
Bone Mineral Density (g/cm2)
Leptin (ng/mL)
25(OH)D3 (nmol/L)

21.6 ± 3.2
61.4 ± 10.0
60.6 ± 9.9
166.0 ± 6.7
21.9 ± 2.9
77.2 ± 7.7
18.4 ± 6.8
30.8 ± 7.8
1.1 ± 0.1
10.1 ± 6.8
105.4 ± 38.0
Percent (N)

Race2
White
Asian
Other
Latina3
Education
Some college/currently in college
College degree
Some graduate school
Graduate degree
Sunscreen user
Tanning bed/booth user

82.6 (38)
6.5 (3)
10.8 (5)
8.7 (4)
69.6 (32)
4.3 (2)
15.2 (7)
10.9 (5)
54.3 (25)
13.0 (6)

1

N = 46 for all variables except tanning bed use (N = 27)
“Other” includes those that marked two race categories
3
“Latina” is a category of its own. A subject can therefore identify herself as
Latina in addition to her race.

2
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Table 7.2. Estimated Dietary Intake of Selected Nutrients1
Nutrient2

Mean ± SD

DRI3

Percent with Intakes
Below RDA

Energy (kcal)
Carbohydrate (g)
Protein (g)
Total fat (g)
Vitamin D (IU)
Calcium (mg)
Phosphorus (mg)
Niacin (mg)
Riboflavin (mg)
Vitamin B6 (mg)
Vitamin B12 (µg)
Vitamin A (µg RAE)

2158 ± 781
281 ± 117
101 ± 39
69 ± 30
367 ± 242
1239 ± 606
1649 ± 610
33 ± 14
3.2 ± 1.7
3.7 ± 3.8
9.1 ± 6.1
4585 ± 1983

--------200
1000
700
14
1.1
1.3
2.4
700

n/a
n/a
n/a
n/a
22
35
2.2
4.3
0
4.3
2.2
0

1

Daily intake was estimated from a modified version of the Harvard FFQ (Willett et al., 1988).
Only energy and vitamin A are normally distributed.
3
Recommended intakes (DRIs) for women this age

2

Twenty-four percent of participants had serum vitamin D levels below 80 nmol/L
(Table 7.3), indicative of suboptimal vitamin D status, although only one subject
fell below the traditional deficiency cut-off of 37.5 nmol/L. The characteristics of
the study sample varied across strata of vitamin D status only with respect to
sunscreen use (Table 7.4). Of the 11 women who had insufficient levels of
25(OH)D3, 10 (91%) reported regular use of sunscreens. Of the 35 women who
had sufficient levels of 25(OH)D3, 15 (43%) reported regular use of sunscreen.
Mean 25(OH)D3 was significantly different between sunscreen users (95.4 ± 35.9
nmol/L) and non-sunscreen users (117.3 ± 37.8 nmol/L, p=0.05). All tanning bed
users (N=6) had sufficient vitamin D status. Mean 25(OH)D3 did not differ
between strata of other sun exposure variables (travel to a sunny location,
average daily hours spent outside in minimal clothing in the week prior to blood
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draw, average daily hours spent outside in minimal clothing during the summer
prior to blood draw, SPF).

Table 7.3. Vitamin D Status1 of Women in Study Sample (N = 46)

Deficient, < 50 nmol/L
Suboptimal, 50 – 79.9 nmol/L
Sufficient, ≥ 80 nmol/L
1

% (n)

Mean (± SD)

6.5 (3)
17.4 (8)
76.1 (35)

41.2 ± 12.6
66.6 ± 8.1
119.8 ± 31.0

Based on serum concentrations of 25(OH)D3.

Table 7.4. Characteristics of Study Subjects, Stratified by Vitamin D Status
Characteristic1

Mean (± SD)
25(OH)D3 (nmol/L)
Leptin (ng/mL)
Vitamin D Intake (IU)
Food
Supplements
Total
Calcium Intake (mg)
Age (years)
BMI (kg/m2)
Fat Mass (kg)
Body Fat (%)
Bone Mineral Density (g/cm2)
Percent
Sunscreen User
BMI < 18.5 kg/m2

Vitamin D Status (nmol/L)

P Value2

Insufficient3
25(OH)D3 < 80
N= 11

Sufficient
25(OH)D3 ≥ 80
N= 35

60.0 ± 14.8
7.8 ± 6.0

119.8 ± 31.0
10.8 ± 7.0

<0.001
0.22

232 ± 181
120 ± 165
351 ± 234
1381 ± 904
23.6 ± 3.9
21.5 ± 3.7
19.0 ± 7.6
31.9 ± 7.9
1.14 ± 0.07

234 ± 146
138 ± 255
372 ± 247
1194 ± 486
21.0 ± 2.7
22.0 ± 2.6
18.2 ± 6.7
30.4 ± 7.8
1.14 ± 0.07

0.97
0.82
0.80
0.52
0.06
0.61
0.73
0.57
0.97

91.0
18.2

42.9
5.7

0.01
0.20

1

N = 46 for all variables.
Statistical significance assessed using ANOVA for all variables except “sunscreen user”, which
used chi-square analyses.
3
The column titled “insufficient” includes subjects from the deficient and suboptimal groups.
These two groups were collapsed into one because there was no significant difference between
them with respect to the variables in this table and because sample sizes in these groups were
very small.

2
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Table 7.5. Mean Serum 25(OH)D3 by Month of Blood Draw1

Mean (± SD)
March 2006/2007
April 2006
May 2006
October/November 2006
December 2006
January 2007
February 2007

% (n)

25(OH)D3 (nmol/L)2

34.8 (16)
32.6 (15)
4.3 (2)
4.3 (2)
4.3 (2)
4.3 (2)
15.2 (7)

105.6 ± 49.1a,b
102.1 ± 30.8a
143.2 ± 14.9a,b
138.8 ± 2.0b
111.6 ± 66.0 a,b
61.8 ± 16.9 a,b
102.3 ± 15.5a

1

October and November 2006 were combined because of low participant
number in each month. March 2006 and 2007 were also combined.
Mean 25(OH)D3 was not significantly different between these two months
(90.0 ± 7.7 vs. 109.2 ± 54.1, p>0.05).
2
Month categories with different superscripts are significantly different as determined by
Tamhane’s test.

Mean Serum 25(OH)D3 (nmol)

150.0

100.0

143.2

138.8

111.6

50.0

105.6

102.3

102.1

61.8

0.0
March

April

May

Oct&Nov

December

January

February

Month of Blood Draw

Figure 7.1. Mean Serum 25(OH)D3 by Month of Blood Draw
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Figure 7.2. Average daily hours spent outside with
minimal clothing in week prior to blood draw
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Figure 7.3. Average daily hours spent outside with
minimal clothing during summer prior to blood draw
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Most women participated in the study during the months of March 2006/2007 and
April 2006. The three deficient subjects were seen in January and March.
Although mean serum 25(OH)D3 level was lowest in January, this level did not
differ significantly from other months. However, mean serum 25(OH)D3
concentration was significantly higher in October/November 2006 than in April
2006 or February 2007 (Table 7.5, Fig 7.1). When combining months into
seasons, no significant differences in serum 25(OH)D3 levels were observed
(data not shown).

Most participants (71.7%) did not spend any time outside in minimal clothing
during the week prior to blood draw (Figure 7.2). Those who did, did so in March,
April, and May. All participants but one spent a daily average of one or more
hours outside during the summer prior to blood draw (Figure 7.3). The nonCaucasian and all but one of the Latina subjects spent three or more hours
outside.

When assessing the relationship between dietary intake of vitamin D and serum
levels of 25(OH)D3, we found that mean serum 25(OH)D3 was significantly lower
in women whose total dietary vitamin D intake fell below the AI (200 IU) than in
women who consumed 200 IU/d or more of vitamin D (83.1±27.7 vs 111.6±38.4
nmol/L, p=0.03). When vitamin D intakes from food and supplements – the two
components of total dietary vitamin D intake – were considered separately, no
difference in mean serum 25(OH)D3 between women who consumed less than
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200 IU/d and women who consumed 200 IU/d or more was observed for either
intake from food (100.1±32.0 vs 110.7±43.3 nmol/L, p=0.35) or intake from
supplements (102.0±40.0 vs 112.5±34.8 nmol/L, p=0.38). Mean serum 25(OH)D3
furthermore did not differ between women consuming less and women
consuming more than 800 IU of vitamin D (105.9±37.6 vs 95.1±63.8 nmol/L,
p=0.70). In addition, serum 25(OH)D3 was not significantly correlated with vitamin
D intake from food, vitamin D intake from supplements, or total vitamin D intake
(r=0.04, p=0.79; r=0.14, p=0.34; r=0.17, p=0.26). In fact, neither serum 25(OH)D3
nor leptin was significantly correlated with intake of any of the macro- and
micronutrients evaluated (data not shown). Serum 25(OH)D3 was positively
correlated with intake of cold cereal (r=0.37, p=0.01), and serum leptin was
positively correlated with intake of cold and cooked cereals (r=0.36, p=0.01, and
r=0.31, p=0.04, respectively).

The correlations between serum 25(OH)D3, leptin, and measures of adiposity are
shown in Tables 7.6 and 7.7. In unstratified analyses (Table 7.6), serum leptin
concentration was significantly positively correlated with all measures of
adiposity, with the strongest correlation (r=0.82, p<0.001) observed for %BF.
Serum leptin was also positively correlated with BMD (r=0.44, p=0.002). Serum
25(OH)D3 was not significantly correlated with serum leptin, BMD, or any of the
adiposity measures.
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Table 7.6. Association Between Leptin, 25(OH)D3 and Measures of Body
Composition, Unstratified

25(OH)D3
r
p
ln(Leptin)
r
p
BMI
r
p
FM
r
p
% Body Fat
r
p

25(OH)D3

ln(Leptin)

BMI

FM

% Body
Fat

BMD

1.00

0.20
0.19

0.05
0.75

-0.02
0.89

-0.004
0.98

-0.03
0.84

1.00

0.55
<0.001

0.77
<0.001

0.82
<0.001

0.44
0.002

1.00

0.84

<0.001
1.00

0.68
<0.001

0.53
<0.001

0.93
<0.001

0.53
<0.001

1.00

0.41
0.01

P-values are 2-tailed.

Analyses stratified by %BF reveal that the relationships between serum
25(OH)D3, leptin, and the body composition variables were modified by %BF. In
stratified analyses (Table 7.7), serum 25(OH)D3 was significantly, positively
correlated with leptin, BMI, and FM in women with normal body fat (%BF≤30).
The significant, positive correlation of serum leptin with BMD and all adiposity
measures remained in stratified analyses for women with normal body fat. In
women with high body fat (%BF>30), serum leptin was significantly, positively
correlated only with FM and %BF, but not with BMI and BMD. Serum leptin
differed between normal and high %BF categories (5.2±2.9 and 13.8±6.7 ng/mL,
respectively, p<0.001), but serum 25(OH)D3 did not (107.1±39.9 and 104.1±37.2
nmol/L, respectively, p=0.79). However, serum 25(OH)D3 differed between the
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>30%
BF

≤30
%BF

>30%
BF

≤30
%BF

>30
%BF

≤30
%BF

>30
%BF

≤30
%BF

>30
%BF

≤30
%BF

Table 7.7. Association Between Leptin, 25(OH)D3 and Measures of Body
Composition, Stratified by Category of %BF1

1
2

25(OH)D3 2
r
p
25(OH)D3 2
r
p
ln(Leptin)
r
p
ln(Leptin)
r
p
BMI
r
p
BMI
r
p
FM2
r
p
FM2
r
p
% Body Fat
r
p
% Body Fat
r
p

25(OH)D3

ln(Leptin)

BMI

FM

% Body
Fat

BMD

1.00

0.55
0.01

0.47
0.04

0.42
0.06

0.35
0.13

0.27
0.25

1.00

0.12
0.56

-0.08
0.69

-0.10
0.61

-0.09
0.67

-0.14
0.51

1.00

0.46
0.04

0.84
<0.001

0.84
<0.001

0.49
0.03

1.00

0.20
0.32

0.35
0.08

0.42
0.03

0.15
0.46

1.00

0.75
<0.001

0.40
0.08

0.70
0.001

1.00

0.77
<0.001

0.61
0.001

0.29
0.15

1.00

0.87
<0.001

0.73
<0.001

1.00

0.79
<0.001

0.35
0.08

1.00

0.46
0.04

1.00

0.10
0.61

P-values are 2-tailed.
Spearman’s correlation coefficient is given for 25(OH)D3 and FM.

low (<18.5 kg/m2) and normal (18.5-24.99 kg/m2) BMI categories (66.8±37.6 and
113.4±37.4 nmol/L, respectively, p=0.04). Body fat percentage was ≤30% in all
“underweight” women (BMI < 18.5 kg/m2) and >30% in all “overweight” (BMI
25.0-29.9 kg/m2) and “obese” (BMI ≥ 30.0 kg/m2) women. However, within the
normal BMI range (BMI 18.5 – 24.9 kg/m2), 16 women had ≤30% BF and 19 had
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>30% BF. BMI and %BF were positively correlated (r=0.35, p=0.01) within the
normal BMI category (data not shown).

Table 7.8. Association Between 25(OH)D3 and ln(Leptin), Unstratified1
B

SE

p-value

Unadjusted

9.8

7.3

0.188

BMI-adjusted
FM-adjusted
%BF-adjusted

12.1
25.7
30.8

8.8
11.1
12.4

0.178
0.025
0.017

Multivariableadjusted2

22.8

14.5

0.124

1
2

Dependent variable: 25(OH)D3
Adjusted for age, current and former smoking status, sunscreen use, and %body fat.

In simple linear regression analyses, serum leptin was not significantly
associated with serum 25(OH)D3 (Table 7.8). Controlling for BMI did not alter the
association. However, in bivariable models that included either fat mass or
percent body fat, serum leptin was significantly positively associated with
25(OH)D3 (B=25.7, p=0.03 and B=30.8, p=0.02). When fat mass is held constant,
serum 25(OH)D3 increased 25.7 nmol/L for every one unit increase in serum
ln(leptin). At constant percent body fat, serum 25(OH)D3 increased 30.8 units for
every one unit increase in serum ln(leptin).

We observed some evidence of effect modification of the leptin-25(OH)D3
relationship by %BF, although results were not statistically significant. In a
multivariable regression analysis adjusting for age, sunscreen use, %BF, and
current and former smoking status, leptin was significantly and positively

74

associated with 25(OH)D3 (B=63.1, p=0.007) only in women with normal %BF,
but was not associated with 25(OH)D3 in women with %BF >30 (Table 7.9). We
observed no effect modification of the leptin-25(OH)D3 relationship by BMI.

Table 7.9. Association Between 25(OH)D3 and ln(Leptin), Stratified by %BF
%BF ≤ 302

Multivariableadjusted1
1
2

%BF > 30

B

SE

p-value

B

SE

p-value

p for
interaction

63.1

19.8

0.01

-14.3

18.1

0.44

0.13

Adjusted for age, current and former smoking status, sunscreen use, and %body fat.
This group included no current smokers.
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CHAPTER 8

DISCUSSION

Results from this study provide some evidence for a positive association between
25(OH)D3 and leptin in models controlling for %BF or FM, indicating that the
relationship is confounded by adiposity. In contrast to the findings of Gomez et al.
(2004), we did not find a relationship between leptin and 25(OH)D3 in unadjusted
analyses. The leptin-25(OH)D3 relationship differed between women with normal
(≤30% BF) and women with high (>30% BF) %BF, however this difference was
not significant. In multivariable regression analysis, leptin was associated with
25(OH)D3 only in women with normal body fat (B=63.1, p=0.007), but not in
women with high body fat. Considering that leptin and 25(OH)D3 are processed
differently in obese than in lean persons because of high body fat content and
leptin resistance, a difference in the relationship between the two compounds
according to weight status is plausible. Previous findings by Gomez et al. (2004)
indicating an inverse correlation between serum leptin and 25(OH)D3 are not
supported by the current study.

Mean serum leptin was 10.1±6.8 ng/mL in the current study, and mean BMI was
21.9±2.9 kg/m2. Ruhl and Everhart (2002) reported mean serum leptin levels of
15.2±0.4 ng/mL and a mean BMI of 25.8±0.2 kg/m2 in a sample of 1906
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premenopausal women drawn from NHANES III. The differences in leptin levels
are consistent with the differences in BMI, since both measures have been
shown to be positively correlated (Considine et al., 1996; Havel et al., 1996;
Maffei et al., 1995). Healthy, premenopausal, normal-weight women studied by
Krzyzanowska-Swiniarska et al. (2007) had lower mean leptin levels than women
in the current study (7.8±3.9 ng/mL vs 10.1±6.8 ng/mL), although the mean BMI
in both studies was almost equal (21.9±2.9 vs 21.3±1.7 kg/m2). However, %BF in
the current study was higher (30.8±7.8 vs 24.5±5.4), and was likely the reason
for the higher mean leptin values. Although leptin has been shown to positively
correlate with BMI, its physiologic relationship is with the amount of adipose
tissue, not muscle mass, which also contributes to BMI.

Leptin was positively correlated with all measures of adiposity in women with
normal %BF. The positive correlation with BMI, FM, and %BF is consistent with
the results from previous correlation studies and underscores the fact that most
serum leptin originates in the adipocyte (Considine et al., 1996, Havel et al.,
1996, Maffei et al., 1995). Leptin was furthermore positively correlated with BMD
in women with normal %BF and not correlated with BMD in women with high
%BF. Some studies have reported a positive association between leptin and
BMD (Thomas et al., 2001; Yamauchi et al., 2001), but this relationship has not
been observed consistently (Martini et al., 2001; Ruhl & Everhart, 2002). Results
from this study provide support for a positive relationship between leptin and
BMD in women with normal %BF.
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Serum 25(OH)D3 was not correlated with any of the body composition variables
in women with high %BF, and positively correlated with ln(leptin), BMI, and FM in
women with normal %BF. Considering 25(OH)D3’s well-established impact on
BMD (Lips 2006), it is somewhat surprising that no correlation between these
variables was observed. However, there was little variation in BMD (1.1±0.1
g/cm2) in this cohort, which may explain the lack of correlation with 25(OH)D3.

Considering evidence of 25(OH)D3‘s inverse relationship with body fat content
(Wortsman et al., 2000), it is furthermore surprising that no correlation between
25(OH)D3 and measures of adiposity was observed in women with high %BF,
that correlations were positive in women with normal %BF, and that body
composition variables did not differ between vitamin D sufficient and insufficient
groups. However, there was little variation in BMI (23.3±2.7 kg/m2), %BF
(36.4±3.9), and FM (22.9±4.8 kg) in women with high %BF, which may explain
the lack of correlation with 25(OH)D3.

Although both FM and %BF were strongly positively correlated with BMI (r=0.84
and 0.68, respectively, p<0.001), only FM and %BF, but not BMI, were significant
confounders of the relationship between serum levels of 25(OH)D3 and leptin.
The study sample yielded a wide range of FM and %BF values, while BMI had
only a small range. There may not have been enough variability in BMI to
produce a confounding effect on the relationship between serum levels of
25(OH)D3 and leptin.
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In addition to the strong correlation with BMI, %BF reflected the weight status of
women with extreme BMIs: in underweight women (BMI < 18.5 kg/m2), %BF was
≤30%; in overweight (BMI 25.0-29.9 kg/m2) and obese (BMI ≥ 30.0 kg/m2)
women, it was >30%. However, within the ‘’healthy’’ BMI range, women divided
about evenly into those with normal (n=16) and those with high (n=19) %BF,
indicating that BMI was not a good indicator of body composition in this category.
Nonetheless, %BF was positively correlated with BMI within the normal BMI
category. Hence, BMI may be associated with FM and %BF at all levels of BMI,
but a normal BMI may not necessarily coincide with a healthy body composition.

Although mean serum 25(OH)D3 in this study was 105.4 ± 38.0 nmol/L, 24% of
subjects

had

biochemical

evidence

of

insufficient

vitamin

D

status

(25(OH)D3 < 80 nmol/L). Many participants in this study were nutrition students
and may therefore have had better vitamin D status than the typical young
woman. This suggests that the actual prevalence of suboptimal vitamin D status
in the general population of young women may be even higher. Serum 25(OH)D3
levels were expected to be low in the late winter and early spring months and
higher in late spring, summer, and early fall. Although this general pattern was
observed,

significant

differences

were

found

only

when

comparing

October/November with April and February. Due to the variability in sample size
between months and the small sample size overall, mean 25(OH)D3 values by
month and differences between months should be interpreted carefully.
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Although total vitamin D intake from diet and supplements varied widely among
subjects (22 – 1446 IU), nearly 80% of participants consumed at least the AI of
200 IU, and the mean intake was 367 IU. However, the inconsistencies in vitamin
D intake were not reflected in serum 25(OH)D3 levels: vitamin D intake from food
and supplements did not differ between insufficient and sufficient subjects, and
vitamin D intake was not a significant predictor of 25(OH)D3 levels. The lack of
correlation between vitamin D intake and serum 25(OH)D3 underscores the
importance of using biomarker measurements to assess vitamin D status since
serum levels of 25(OH)D3 are related to many nondietary factors.

The current vitamin D AI for women under age 51 (200 IU) is set to produce
serum levels of just above 37.5 nmol/L to prevent the deficiency diseases rickets
and osteomalacia. However, newer evidence suggests that optimal serum levels
should be at least 80 nmol/L (Holick, 2005). In order to achieve 25(OH)D3 levels
of 80 nmol/L and above in the absence of adequate UV-B radiation (such as in
January), Holick (2004b) has proposed a daily intake of 800 – 1000 IU. Vitamin D
intake observed in the current study ranged from 22 IU to 1446 IU, but only 4.3%
of women consumed ≥800 IU. Along with the insignificant relationship between
dietary vitamin D and 25(OH)D3 levels, this observation supports the idea that the
subjects with sufficient levels of vitamin D achieved those through sun exposure
rather than diet.
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Although a single sun exposure variable was not created for this study, we can
speculate about the relationship between sun exposure and 25(OH)D3 in this
sample by drawing some conclusions from the battery of sun exposure variables.
During the week prior to blood draw, most participants (71.7%) did not report
spending any time outside in minimal clothing, so the sufficient 25(OH)D3 levels
were probably not caused by recent sun exposure. Furthermore, substantial
exposure to UV-B radiation in the week prior to blood draw likely would have
resulted in much higher individual 25(OH)D3 levels than observed in this study. In
the summer prior to blood draw, all but one participant spent a daily average of
one or more hours outside wearing minimal clothing. The non-Caucasian
subjects, who require a longer sun exposure to achieve a MED, spent three or
more hours outside. Hence, nearly all of our subjects spent enough time outside
in the summer prior to blood draw to get at least one daily MED (= 10,000 –
20,000 IU), provided they did not use sunscreen.

Serum 25(OH)D3 levels did not differ by the number of hours spent outside
wearing minimal clothing in the week and the summer prior to blood draw,
suggesting that other factors, such as sunscreen use, may have played a role in
the extent of vitamin D synthesis. It may also have been difficult for subjects to
accurately estimate average hours spent outdoors. Minimal sun exposure (e.g.
10-15 minutes on one day of the week for light-skinned women) may have been
interpreted and indicated on the questionnaire as “no sun exposure,” when in fact
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this minimal sun exposure may have sufficed to produce at least some vitamin D
in those women who participated in the study during the spring and fall.

Slightly more than half of subjects in this study reported using sunscreen. Of
those with insufficient 25(OH)D3 levels, 91% reported using sunscreen,
suggesting that sunscreen use was an effective block against vitamin D
synthesis in this group. Sunscreen use was also common among women with
sufficient 25(OH)D3 levels. Almost half (43%) of women in this group reported
using sunscreen, yet that practice did not appear to substantially interfere with
vitamin D synthesis. Sunscreen only provides protection from UV-B radiation
when applied properly and in sufficient amounts, but most people apply the
product improperly and therefore do not reap the full benefits of the stated SPF
(Gaughan & Padilla, 1998; Grencis & Stokes, 1999; Stenberg & Larko, 1985).

The current study has several important strengths. Vitamin D deficiency in the
Gomez et al. (2004) study was defined by old standards, using 38 nmol/L as the
cut-off value. The present study used a more appropriate cut-off value of 80
nmol/L (Barger-Lux et al, 1998; Holick, 2005). Use of this higher cut-off value
provided a more sensitive estimate of the prevalence of suboptimal vitamin D
levels in this population.

To determine body composition, Gomez et al. (2004) used the Holtain BC
bioelectrical

impedance

analyzer.

Bioelectrical
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impedance

has

some

shortcomings. Abnormal hydration, such as from excessive sweating or intake of
large amounts of water, leads to distorted estimates of fat mass. Furthermore,
bioelectrical impedance is an indirect method that employs population-specific
regression equations to obtain measurements of fat and lean mass. Thus, the
quality and choice of the equation determines the accuracy of the final data (Kyle
et al., 2004). In the current study, DXA was used instead. DXA measures fat and
lean mass directly, provides good reproducibility and validity, and yields more
reliable results. Serum leptin and serum 25(OH)D3 were measured with the same
assay kits Gomez et al. used, resulting in an improved ability to compare results.

In addition to differences in methodology, the population of interest varies
considerably

between

the

two

studies.

Gomez

et

al.

investigated

a

heterogeneous population consisting of men and women and spanning six age
decades. The current study focused on a relatively homogeneous group of
healthy young women.

The limitations of this study include its cross-sectional design, which does not
allow for any conclusions about causality in the relationship between serum leptin
and 25(OH)D3. Because this was a preliminary analysis, the sample size was
small, limiting statistical power. Furthermore, we recruited only healthy, young
women, all of whom were self-selected and many of whom were nutrition majors.
These factors may have resulted in recruitment of women who were generally
more health- and diet-conscious, which could have resulted in selection bias.
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However, dietary factors were not confounders of the leptin-25(OH)D3
relationship, suggesting that women eating a healthy diet likely exhibit the same
association between leptin and 25(OH)D3 as women who are not concerned with
their diet. There may be other health-related factors (e.g. exercise) not accounted
for in this study that may distinguish our sample from healthy, young women in
general and that may confound the leptin-25(OH)D3 relationship. In this case,
selection bias would limit the generalizability of our results, but could also have
made our group more homogenous, which could be an advantage considering
our small sample size.

The lack of quality control data and the method of computation used in the RIAs
leave some doubt as to the accuracy of the leptin and 25(OH)D3 data. Possible
measurement error in the assays could not be estimated because quality control
data were not available. The assays furthermore rely on a regression equation to
derive concentrations of the analyte from radiation counts. The quality of the
equation influences the accuracy of the final values, and there may be equations
yielding better results than the one used in this study.
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CHAPTER 9

CONCLUSIONS

Results from the current study confirm the positive association of leptin with
%BF, underscoring the fact that most serum leptin originates in the adipocyte.
Our results furthermore suggest that, after controlling for adiposity, 25(OH)D3 is
positively associated with leptin, and that this relationship may be modified by
%BF. In addition, we observed that %BF did not reflect the weight status of
women with healthy BMIs, indicating that BMI was not a good indicator of body
composition in these women. Vitamin D intake was not a good predictor of
25(OH)D3 levels, indicating that the assessment of vitamin D status may be more
reliable when biomarker instead of dietary measurements are used. Our findings
furthermore provide additional evidence to confirm that sunscreen use is an
effective block against vitamin D synthesis.

Because of the small sample size of the current study, further studies using
larger cohorts are needed to confirm the association between 25(OH)D3 and
leptin and to explore possible effect modification by %BF. Additional studies are
also needed to elucidate the physiologic significance of this association and to
determine whether manipulation of either serum levels of leptin or 25(OH)D3
through intervention influences adiposity.
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